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The HVEM-BTLA axis restrains T cell help to germinal center B cells and functions as a 
cell-extrinsic suppressor in lymphomagenesis 
 
Michelle Amy Mintz 
 
ABSTRACT 
TNF receptor family member HVEM is one of the most frequently mutated surface 
proteins in germinal center (GC) derived B cell lymphomas, yet the role of HVEM in normal 
GCs is unknown. We found that HVEM-deficiency intrinsically increased B cell competitiveness 
during pre-GC and GC responses. The Ig superfamily molecule BTLA was identified as the 
ligand regulating these responses, and B cell-intrinsic signaling via HVEM and BTLA was not 
required. Instead, BTLA signaling into the T cell through SHP1 reduced TCR signaling and the 
amount of preformed CD40L mobilized to the immunological synapse and thus diminished the 
help delivered to B cells. Moreover, T cell-deficiency in BTLA cooperated with B cell Bcl-2-
overexpression in leading to GC B cell outgrowth. These results establish that HVEM restrains 
the T helper signals delivered to B cells in a manner that influences GC selection outcomes, and 
they suggest that BTLA functions as a cell-extrinsic suppressor of GC B cell lymphomagenesis. 
 
 
 
 
 
 
 ix 
TABLE OF CONTENTS 
CHAPTER 1: Introduction ....................................................................................................... 1 
Introduction .......................................................................................................................... 2 
Mutations in B cell lymphomagenesis .................................................................................. 4 
Tfh cell participation in follicular lymphoma ..................................................................... 5 
IL-4 – STAT-6 ...................................................................................................................... 7 
CD40L – CD40...................................................................................................................... 9 
PD-1 – PD-L1/PD-L2 .......................................................................................................... 11 
ICOS – ICOSL.................................................................................................................... 14 
FasL – Fas ........................................................................................................................... 16 
SAP – SLAMF .................................................................................................................... 18 
Tfh cell derived lymphomas ............................................................................................... 19 
BTLA – HVEM .................................................................................................................. 21 
CHAPTER 2: The HVEM-BTLA axis restrains T cell help to germinal center B cells and 
functions as a cell-extrinsic suppressor in lymphomagenesis.................................................. 24 
Summary............................................................................................................................. 25 
Introduction ........................................................................................................................ 25 
Results ................................................................................................................................. 27 
HVEM-deficiency increases GC B cell competitiveness ................................................ 27 
HVEM-deficiency provides the earliest GC B cells with a proliferation advantage .... 31 
 x 
Loss of HVEM in an ongoing GC provides B cells with a competitive advantage ....... 31 
HVEM signaling intrinsic to the B cell is not required for GC B cell suppression ...... 34 
BTLA on CD4+ T cells is required for HVEM-deficient GC B cell competitiveness ... 36 
BTLA-HVEM at the immunological synapse recruits SHP1 to inhibit signaling in Tfh 
cells .................................................................................................................................. 38 
BTLA signaling into the T cell through SHP1 is required for HVEM-deficient GC B 
cell competitiveness......................................................................................................... 41 
HVEM-BTLA interaction reduces the amount of CD40-CD40L brought to synaptic 
interface .......................................................................................................................... 43 
BTLA-deficiency in T cells leads to GC B cell expansion in the setting of Bcl-2-
overexpression ................................................................................................................ 45 
Discussion ........................................................................................................................... 47 
SUPPLEMENTAL FIGURES AND LEGENDS .............................................................. 53 
MATERIALS AND METHODS........................................................................................ 58 
Mice ................................................................................................................................. 59 
Generation of BTLAY3 mice ......................................................................................... 59 
Bone marrow chimeras .................................................................................................. 60 
Retroviral constructs and transductions ....................................................................... 60 
Cell isolation, adoptive transfer ..................................................................................... 61 
Immunizations ................................................................................................................ 61 
Flow cytometry ............................................................................................................... 62 
qPCR and RNA-sequencing ........................................................................................... 62 
GSEA and Gene Ontology .............................................................................................. 63 
 xi 
NP VH186.2 mutation analysis ....................................................................................... 63 
Tfh cell CD40L surface mobilization ............................................................................. 64 
Assessment of BCR clonality by PCR ............................................................................ 65 
Human CD4+ T cell isolation, stimulation, and transfection ........................................ 65 
Human Tfh cell isolation ................................................................................................ 66 
Quantification of BTLA and HVEM surface expression .............................................. 67 
Supported lipid bilayer preparation and use ................................................................. 68 
Immunofluorescence staining......................................................................................... 69 
TIRF and confocal imaging ............................................................................................ 69 
Image analysis ................................................................................................................. 70 
In-situ analysis of interaction of SHP1 and SHP2 with PD-1 ....................................... 70 
Quantification and statistical analysis ........................................................................... 72 
Data availability .............................................................................................................. 72 
Acknowledgements ............................................................................................................. 72 
Declaration of interests....................................................................................................... 73 
CHAPTER 3: CONCLUSION................................................................................................. 74 
Therapeutic approaches ..................................................................................................... 81 
Concluding remarks ........................................................................................................... 82 
REFERENCES ....................................................................................................................... 83 
 
  
 xii 
TABLE OF FIGURES 
CHAPTER 1: 
FIGURE 1.1 ............................................................................................................................... 7 
 
CHAPTER 2: 
FIGURE 2.1 ............................................................................................................................. 29 
FIGURE 2.2 ............................................................................................................................. 32 
FIGURE 2.3 ............................................................................................................................. 34 
FIGURE 2.4 ............................................................................................................................. 37 
FIGURE 2.5 ............................................................................................................................. 39 
FIGURE 2.6 ............................................................................................................................. 41 
FIGURE 2.7 ............................................................................................................................. 46 
SUPPLEMENTAL FIGURES: 
 
FIGURE S1. ……………………………………………………………………………………. 54 
 
FIGURE S2. ……………………………………………………………………………………. 55 
 
FIGURE S3. ……………………………………………………………………………………. 56 
 
FIGURE S4. ……………………………………………………………………………………. 57 
 
FIGURE S5. ……………………………………………………………………………………. 58 
 
CHAPTER 3: 
FIGURE 3.1 ............................................................................................................................. 74 
 
 
 
 1 
CHAPTER 1: Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Introduction 
Germinal centers (GCs) are anatomic regions in lymphoid organs where activated B cells 
undergo somatic mutation and rapid proliferation, and give rise to memory B cells and long-lived 
antibody secreting plasma cells. GCs are organized into two main anatomical compartments, 
named based on their histological appearance in early staining techniques, a dark zone (DZ) and 
light zone (LZ). In the DZ, B cells express activation induced cytidine deaminase (AID) which 
mutates immunoglobulin (Ig) genes through deamination of cytosines, leading to Ig 
diversification. In the LZ, GC B cells test their newly mutated Ig proteins for improved affinity 
to antigen presented on the surface of specialized stromal cells called follicular dendritic cells 
(FDCs). If the B cell recognizes antigen, it internalizes the antigen for presentation to the limited 
number of CD4+ T follicular helper (Tfh) cells that reside in the LZ. Tfh cell positive selection 
drives expression of Myc, which determines GC B cell size and subsequent numbers of clonal 
cell divisions that occur in the DZ (Mayer et al., 2017). Just as GC B cells are some of the most 
proliferative mammalian cells, dividing every 4-6 hours, they are also particularly sensitive to 
cell death with ~50% of GC B cells dying in 6 hours. DZ GC cells die due to deleterious AID-
induced mutations and LZ GC B cells die by default if there is a lack of antigen engagement and 
subsequent T cell help.    
Tfh cells are a subset of CD4+ T cells that require the transcription factor Bcl-6, localize 
to B cell follicles and GCs, and depend on GC B cells for their maintenance (Crotty, 2019; Wan 
et al., 2019). Tfh cells are not necessarily defined by their production of particular cytokines, but 
rather by their ability to support GC formation, select GC B cells, and determine GC B cell 
differentiation into memory B cells and plasma cells through cognate interactions. Tfh cell 
positive selection of GC B cells occurs predominantly through CD40L engagement of CD40 on 
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the GC B cell. However, several cytokine and cell surface proteins contribute to the Tfh cell’s 
ability to promote the clonal expansion and selection of GC B cells.  
Despite the fragility of GC B cells in the absence of sufficient Tfh cell positive selection 
signals, GC B cell selection can go awry. While overexpression of anti-apoptotic molecules such 
as Bcl-2 and cell cycle promoting molecules such as c-Myc have long been recognized to drive 
lymphomagenesis, whether mutations occur that lead to exaggerated T cell help has been less 
clear (Mlynarczyk et al., 2019). There are three main types of non-Hodgkin B cell lymphomas 
that originate in the GC and maintain a GC B cell transcriptional identity: follicular lymphoma 
(FL), GC-type diffuse large B cell lymphoma (GC-DLBCL), and Burkitt lymphoma (BL). 
Follicular lymphoma, in particular, maintains the normal GC architecture, such as the presence 
of Tfh cells and stromal cells, despite dyssynchronous LZ and DZ cycling (Bende et al., 2007; 
Milpied et al., 2018; Ochando and Braza, 2017). However, GCB-DLBCL also maintains a CD4+ 
T cell and Tfh cell signature, compared to Activated B cell (ABC)-DLBCL (Iqbal et al., 2011; 
Schmitz et al., 2018). This has led to the hypothesis that non-malignant immune cells support 
lymphomagenesis. Large scale sequencing of patient samples provided novel insights about the 
regulatory pathways that are commonly targeted during GC B cell lymphomagenesis (Lackraj et 
al., 2018; Schmitz et al., 2018). In this introduction, we present evidence for participation of Tfh 
cells in the formation and progression of GC B cell lymphomagenesis with a focus on the key 
molecular mediators of Tfh cell help. We will also examine the role of GC B cells in supporting 
Tfh cell lymphomagenesis. Lastly, we will introduce the BTLA and HVEM signaling axis, 
which will be the focus on Chapter 2. 
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Mutations in B cell lymphomagenesis  
In follicular lymphoma, the first genetic hit in 90% of cases is the t(14;18)(q32;q21) 
chromosomal translocation of the anti-apoptotic Bcl-2 gene with the IgH locus during Ig gene 
recombination in the bone marrow (BM). Although Bcl-2 overexpression provides B cells with a 
survival advantage, it is not sufficient for lymphomagenesis as 10-100 per million circulating 
peripheral blood B cells in a healthy adult have this translocation (Rabkin et al., 2008). Bcl-2-
overexpressing GC B cells have increased survival and this is likely associated with an increased 
risk of abnormal selection and AID-induced transformation to a malignant state (Bende et al., 
2007). Indeed, Bcl-2 overexpression can occur in all three forms of GC B cell-derived 
lymphomas, driving survival of GC B cells that normally do not express Bcl-2. Interestingly, 
Bcl-2 overexpression is more common in the adult form of BL compared to the pediatric form 
(Bouska et al., 2017). This correlates with the increased frequency of Bcl-2 translocations in 
older people, and the evidence that Bcl-2-overexpressing B cells give rise to memory B cells that 
can undergo iterative rounds of GC entry, allowing for multiple rounds of mutagenesis and 
potential errors in selection (Liu et al., 1994; Sungalee et al., 2014).   
AID-mediated cytidine deamination can be recognized by base excision repair or 
mismatch repair mechanisms leading to either point mutations or double strand breaks followed 
by recombination. While AID is hypothesized to drive the majority of mutations that transform a 
mature B cell into a malignant cell, some lymphoma-associated mutations may arise 
independently of AID, perhaps as a consequence of the increased error prone DNA repair in GC 
B cells (Álvarez-Prado et al., 2018; Tsukamoto et al., 2017). Extensive sequencing has been 
done in GC-derived lymphomas to understand what mutations are driving lymphomagenesis. 
Surprisingly, only around half a dozen are common targets of mutation in all three types of GC 
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lymphomas (Bouska et al., 2017; Lackraj et al., 2018; Schmitz et al., 2018). These include BCL-
2, TNFRSF14, SOCS1, STAT6, CREBBP, EZH2, and GNA13.  
Loss of function mutations in TNFRSF14 and SOCS1 and activating mutations in STAT6 
enhance or override Tfh cell helper signals to GC B cells (Losman et al., 1999; Mintz et al., 
2019; Turqueti-Neves et al., 2014) and will be discussed in detail below. CREBBP and EZH2 are 
epigenetic modifiers that have complex effects on GC B cell signaling and gene expression. Loss 
of function mutations in CREBBP promotes unrestricted GC growth, in part through increasing 
CD40 signaling, and also reducing MHC-II expression, which alters mutant FL cell ability to 
present antigen to CD4+ T cells (Hashwah et al., 2017). Gain of function mutations in polycomb 
repressor complex-2 (PRC2) component EZH2 inhibits cell cycle checkpoints, promoting 
uncontrolled GC B cell proliferation (Béguelin et al., 2013; 2017). GNA13 is a signaling protein 
downstream of transmembrane G-protein coupled receptors S1PR2 and P2RY8 that confines B 
cells to the GC and inhibits Akt and possibly other signaling molecules, limiting survival signals 
(Green et al., 2011; Lu et al., 2019; Muppidi et al., 2014). While mutations in some of the key 
positive regulators of GC B cells, such as CD40, ICOSL, and SLAMF and negative regulators of 
GC B cells, such as PD-L1/2 and Fas, are less selected in GC lymphomas, we suggest that these 
molecular mediators may often play an important, and yet underappreciated role in disease 
pathogenesis. 
Tfh cell participation in follicular lymphoma 
 
Tfh cells, defined by surface expression as CXCR5+PD-1+ICOS+CD4+ T cells, support 
GC B cells, which in turn maintain Tfh cells, providing a feedforward positive selection loop. In 
a mouse model of follicular lymphoma, in which the Vav promoter drives Bcl-2 overexpression 
in hemopoietic cells, depletion of CD4+ T cells reduced the size of the GCs, suggesting that 
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disease initiation and likely progression depends on T cells (Egle, 2004). Tfh cells in the FL 
tumor microenvironment have been demonstrated by several studies (Ochando and Braza, 2017). 
Tfh cell gene signatures are also maintained in Bcl-2-positive GCB-DLBCL cases (Iqbal et al., 
2011). An association of Tfh cells with EBV+ BL cases has not been reported (Schmitz et al., 
2012), although interestingly EBV transformed GC B cells may support Tfh cell type 
lymphomas (Schmitz and de Leval, 2016). We will focus our introduction on what is known 
about the key molecular regulators of Tfh cell help to GC B cells and how they may play a role 
in GC B cell outgrowth and lymphomagenesis (Fig. 1.1).  
Before discussing CD4 T helper molecules, the role of cytotoxic lymphocytes in 
lymphomas should be mentioned. GC lymphoma cells have a high mutation burden and are 
susceptible to killing by cytolytic CD8 T cells and NK cells (Basso and Dalla-Favera, 2015). It is 
therefore not surprising that GC lymphomas commonly show mutations in beta-2-microglobulin 
(b2m) and CD58 (LFA3). B2m is a component of all MHC class I molecules, and loss of this 
protein leads to loss of MHC class I expression and protection from CD8 mediated killing. Loss 
of MHC class I can, however, lead to recognition by NK cells. GC lymphomas can become 
resistant to NK cells through loss of CD58 expression, a surface counter receptor for CD2, an 
adhesion and activating molecule expressed on NK cells (Challa-Malladi et al., 2011). Cytotoxic 
cells usually have very limited access to B cell follicles and GCs and it is possible that another 
mode of GC lymphoma evasion of cytotoxic cells is through continued CXCR5-CXCL13 
mediated compartmentalization within the follicular microenvironment. CXCL13 is made by 
several types of stromal cells, including FDCs and marginal reticular cells (MRCs) and GC 
lymphomas, especially FLs, maintain their FDC networks and have strong expression of 
CXCL13. A signature feature of Tfh cells is their expression of CXCR5 and efficient ability to 
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access lymphoid follicles (Chang et al., 2003). Human Tfh cells are also a source of CXCL13 
though the role of Tfh CXCL13 in GCs remains unclear. While most cytotoxic cells are CXCR5 
negative, in some situations they can be induced to express CXCR5 and this facilitates their 
access to GC microenvironments and elimination of GC lymphoma cells (Tang et al., 2017). 
 
Figure 1.1. Follicular lymphoma (FL) germinal center B cells receive exaggerated helper 
cues from T follicular helper cells 
Germinal center microenvironment in a LN with a follicular lymphoma tumor. The follicular 
lymphoma germinal center contains stromal follicular dendritic cells (FDC, purple), germinal 
center (GC) B cells (blue), and T follicular helper (Tfh) cells (yellow). (A) Magnification of light 
zone germinal center where a Bcl-2 translocated GC B cell is presenting antigen to a Tfh cell and 
is receiving normal positive selection (left of TCR) and negative selection (right) signals. (B) 
Magnification of a FL GC B cell’s interaction with a Tfh cell in which several of the key 
molecular regulators are altered as will be discussed below. Briefly, there is increased IL-4 
production, increased Tfh cell help via CD40L due to the absence of BTLA-HVEM, and 
mutations in Fas death domain that prevents FasL mediated cell death. 
 
IL-4 – STAT-6 
IL-4 is a CD4 T cell derived cytokine known to support B cell proliferation, class-
switching, and survival (Paul, 2015). Sequencing of human FL identified activating mutations in 
STAT6, the main IL-4R signaling mediator, and loss of function mutations in a suppressor of 
cytokine signaling, including IL-4R signaling, SOCS1 (Lackraj et al., 2018). This is consistent 
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with increased STAT6 signaling measured by p-STAT6 in formalin fixed FL sections compared 
to tonsil (Rawal et al., 2013). Furthermore, IL-4 protein was identified to be 5-fold more 
abundant in FL samples compared to tonsils (Calvo et al., 2008). Interestingly, normal Tfh cells 
express high amounts of IL-4 mRNA, yet produce small amounts of IL-4 protein (Crotty, 2019). 
When malignant B cells and bystander healthy immune cells were sorted and their transcriptional 
signatures analyzed, Tfh cells were found to express high levels of IL-4 transcripts in FL 
(Pangault et al., 2010). Furthermore, FL B cells in close proximity to Tfh cells were actively 
signaling through STAT-6 as measured by p-STAT6, suggesting Tfh cells in FL are the major 
producers of IL-4. A follow up study, confirmed the high expression of IL-4 in CD25-low Tfh 
cells (Ame-Thomas et al., 2012).  
It remains unknown what is driving the elevated expression of IL-4 transcripts by FL Tfh 
cells compared to tonsillar Tfh cells. Unlike the increase seen in IL-21 expression, IL-4 
expression was unchanged when the amount of antigen GC B cells presented to Tfh cell was 
increased, suggesting that TCR signaling in Tfh cells is not sufficient to increase IL-4 mRNA 
expression (Shulman et al., 2014). IL-4 production in Tfh cells is uniquely regulated compared to 
Th2 IL-4, as Tfh cell IL-4 is transcriptionally regulated by CNS2, a 3’ enhancer in the IL-4 
locus, but not by GATA-3 (Vijayanand et al., 2012). Understanding the production of IL-4 by 
Tfh cells and its consequential IL4-R – STAT-6 signaling in FL B cells is further complicated by 
the results that the blockade or deletion of these signaling pathways results in minor alterations 
in the normal GC response (Kopf et al., 1995). In the mouse, production of both IL-4 and IL-21 
are required for a robust GC B cell response (Reinhardt et al., 2009; Zotos et al., 2010). Two 
recent studies have found that IL-4 is preferentially expressed by Tfh cells later in the immune 
response, compared to IL-21 which is preferentially expressed early in the GC (Gonzalez et al., 
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2018; Weinstein et al., 2016). IL-4 has also recently been shown to be uniquely able to induce 
high levels of Bcl6 protein, which is the transcription factor that is required for GC B cell 
formation and maintenance (Chevrier et al., 2017).  
These data support a model in which Tfh cells in FL are most similar to late GC-Tfh 
cells. The independent data supporting high IL-4 and selection for activating STAT6 and loss of 
function SOCS1 mutations adds further support to the notion that IL-4 production by Tfh cells is 
supportive of FL B cells. Additionally, IL-4’s ability to stabilize Bcl-6 protein may play an 
important role in maintaining GC B cell identity and preventing transformation into a post-GC B 
cell lymphoma. While the effect of IL-4 alone in driving GC B cell outgrowth is less clear based 
on the normal GC B cell evidence, it remains to be studied whether IL-21 is being co-produced 
by FL Tfh cells, such that FL B cells are receiving two complementary cytokine signals known 
to support GC B cell expansion.  
 
CD40L – CD40  
CD40, a TNFRSF member, predominantly promotes B cell survival, proliferation and 
class switching through its ability to signal via NFκB. In humans with mutations in CD40L-
CD40 signaling, GCs cannot form and hyper-IgM immunodeficiency develops. FL B cells 
express CD40 and respond to CD40L. CD40 signaling in FL B cells increased the anti-apoptotic 
protein Bcl-XL and prolonged FL B cell survival in vitro, suggesting CD40 promotes the 
survival of FL B cells complementary to their overexpression of Bcl-2 (Ghia et al., 1998; Travert 
et al., 2008). CD40 signaling can promote differentiation into plasma cells and CD40 
amplifications occur in human plasma cell malignancies, yet none have been described in GC-
derived lymphomas (Hömig-Hölzel et al., 2008).  
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CD40L is expressed by naïve and activated CD4+ T cells, but not by CD8+ T cells (Lesley 
et al., 2006; MacLennan, 1994). CD40L expression was increased after TCR signaling 
(Casamayor-Palleja et al., 1995; Iezzi et al., 2009), and the amount of preformed CD40L 
mobilized to the surface of Tfh cells increased with the amount of antigen presented (Mintz et 
al., 2019). One study found FL Tfh cells expressed 2.5-fold higher amounts of CD40L mRNA 
compared to tonsillar Tfh cells, suggesting FL Tfh cells may receive stronger TCR signals 
though it is also possible that the FL samples were more enriched for the type of Tfh cells 
associated with GCs (GC-Tfh) that correspond to only a fraction of Tfh cells in healthy lymphoid 
tissue (Ame-Thomas et al., 2012). CD40L protein is also expressed on T cells in the FL 
environment (Carbone et al., 1995). Strong evidence for a positive role of CD40L in promoting 
lymphomagenesis comes from a mouse study in which constitutive CD40L expression in mature 
T cells was driven by LTR of HTLV1 (Sacco et al., 2000). At 6 months of age, one third of the 
mice developed palpable inguinal masses that were indistinguishable from GC-derived BL 
(Sacco et al., 2000). These data are in contrast to B cell constitutive CD40L transgenic mice 
which do not maintain the GC B cell response (Kishi et al., 2010), suggesting that the cellular 
source and regulation of CD40L delivery is crucial to the signaling outcome. 
As CD40 signaling is a master regulator of B cell responses, therapeutics have been 
developed for the purposes of immune modulation in transplantation, autoimmunity, and 
lymphoma. While several CD40 agonists have been developed to stimulate the immune response 
via costimulation of antigen presenting cells, CD40 blocking agents have also been developed. In 
a Phase I/II trial with a CD40 antagonist HCD122, CD40 blockade induced a response in a third 
of FL patients with refractory disease to rituximab treatment (Fanale et al., 2013). Since 
HCD122 has been shown to induce antibody dependent cellular cytotoxicity (ADCC), it remains 
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to be determined if the clinical efficacy is due to ADCC, blockade of CD40L-CD40 signaling, or 
both.  
 
PD-1 – PD-L1/PD-L2 
The inhibitory immunoglobulin superfamily (IgSF) member PD-1 is a defining marker of 
normal and FL Tfh cells (Myklebust et al., 2013). PD-1 is also highly upregulated on exhausted 
CD8+ T cells that cannot appropriately perform cytotoxic functions, which has led to impressive 
immunotherapy benefit by blocking PD-1 to restore TCR sensitivity and T cell function in some 
cancers (Mulder et al., 2019; Xu-Monette et al., 2019). Several studies have attempted to 
correlate the outcome of FL with PD-1+ T cells, but the results have not been consistent likely 
due to heterogeneity of PD-1+ T cells within the FL environment (Smeltzer et al., 2014; Yang et 
al., 2019). While the number of PD-1+ T cells did not correlate with outcome, the location of PD-
1+ T cells in a follicular pattern was associated with a shorter time to transformation compared to 
a diffuse pattern (Smeltzer et al., 2014). Although these results are difficult to interpret as the 
authors did not stain for CD4 or CD8, the finding that the diffuse PD-1+ cells co-stained for 
TIM-3, a marker of CD8+ T cell exhaustion, whereas the follicular PD-1+ cells did not, suggests 
that the diffuse T cells are CD8+ cells whereas the follicular cells may be Tfh cells. In another 
study, higher levels of PD-1 expression were found in CD4+ T cells compared to CD8+ T cells in 
FL (Yang et al., 2019). Amongst the CD4+CD25- PD-1+ cells in FL, there were 4 subsets: (1) 
CXCR5+ Tfh cells, (2) CD27+CXCR5- cells, (3), CD28-CCR4+ cells, (4) CD28-CCR4- cells. 
Interestingly, CD27+CXCR5+ Tfh cells and CD27+CXCR5-cells were correlated with better 
overall survival while CD28-CCR4+ cells and CD28-CCR4- cells were correlated with poor 
overall survival. These data suggest that non-Tfh CD4+ T cells with low expression of 
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costimulatory molecules likely prevent a productive immune response to the FL or, alternatively, 
directly support FL B cell proliferation. While a higher frequency of PD-1+ Tfh cells in the FL 
microenvironment did not correlate with poor survival, these data do not rule out a possibility 
that PD-1 may be restraining the Tfh cell’s ability to support FL B cell survival. Interestingly, 
40% of ABC-DLBCL have mutations or copy number gains of PD-L1, whereas only 10% of 
GCB-DLBCL have increased PD-L1 expression (Godfrey et al., 2019; Xu-Monette et al., 2019). 
Increased expression of PD-L1 is associated with increased numbers of activated and exhausted 
CD8+ T cells in the tumor microenvironment. However, these data suggest that increased PD-L1 
is not as prevalent of a selection mechanism in GCB-DLBCL compared to post-GC ABC-
DLBCL, perhaps due to the inhibition of PD-1+ Tfh cells in GCB-DLBCL tumors. It remains to 
be determined if PD-L1 expression alters Tfh cells in the GCB-DLBCL tumor microenvironment 
and if PD-L1 is mutated in a manner that leads to loss of expression in some GCB-DLBCL cases 
(Godfrey et al., 2019). 
During the normal GC response, the majority of evidence suggests that PD-1’s 
interaction with PD-L1 restrains the response. However, PD-1’s function in the Tfh cell and how 
it restrains the amount of help provided to GC B cells remains unclear despite several studies. 
PD-L1 is expressed in naïve B cells, and upregulated in GC B cells, whereas PD-L2 is not 
expressed in naïve B cells, but slightly increased in GC B cells (Good-Jacobson et al., 2010). In 
one study, where PD-1 or its ligands were deficient, plasma cell output was decreased at 2 weeks 
and this decrease was sustained for greater than 1 year after NP-CGG immunization. In 
discordance with PC output, GC B cells were not increased, likely due to their increased cell 
death in the absence of PD-1 during this immunization. Interestingly, while the authors found 
that PD-1 deficiency led to increased Tfh cell numbers, these Tfh cells had reduced expression of 
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helper cytokines such as IL-21 (Good-Jacobson et al., 2010). In another study, after helminth 
infection, PD-L1-deficiency led to increased GC B cells and Tfh cells (Hams et al., 2011). After 
immunizing with KLH/CFA and blocking PD-1, PD-L1, or PD-L2, it was found that PD-L1 
blockade increased Tfh cells 5-fold, whereas PD-L2 blockade had no effect, and PD-1 blockade 
provided an intermediate 2-fold increase in Tfh cells, suggesting that PD-L2 is not upregulated 
during KLH/CFA or the blocking agent is not sufficient to reveal an effect (Hams et al., 2011). 
These data are further complicated as PD-1 is also expressed by T follicular regulatory (Tfr) 
cells, CD4+Foxp3+ cells that express CXCR5. PD-1 or PD-L1 deficiency, but not PD-L2 
deficiency, led to increased Tfr cells rather than Tfh cells after immunization with MOG (Sage et 
al., 2012). Interestingly, PD-1 or PD-L1-deficiency or blockade increased GC B cell responses in 
a mouse model of type I diabetes, whereas PD-L2 blockade had no effect (Martinov et al., 2019). 
While these studies suggest that PD-1 restrains Tfh cells, together they do not point to a 
mechanism of how PD-1 on the T cell restrains help to GC B cells. In a more recent study, mixed 
chimeras were generated with PD-L1 deficient and wild-type BM. While PD-L1 deficient B cells 
were increased in representation in the GC, memory B cell, and plasma cell compartments, they 
had reduced affinity to the immunogen, the hapten NP (Shi et al., 2018; Wan et al., 2019). These 
data most clearly suggest that PD-L1 expression on the GC B cell restricts the amount of T cell 
help and the stringency of GC B cell selection by Tfh cells. While the authors did not directly 
show PD-L1 in the GC B cell was regulating PD-1 in Tfh cells, they observed that PD-1 mutant 
antigen-specific Tfh cells supported larger GC B cell responses.  
PD-1 is known to dampen T cell signaling by inhibiting TCR and CD28, and has been 
shown to signal predominantly through the phosphatase SHP2 (Hui et al., 2017; Mintz et al., 
2019; Yokosuka et al., 2012). Although T cell deficiency in SHP2 did not phenocopy many of 
 14 
PD-1’s known roles in CD8+ T cells, in the absence of SHP2, the inhibitory phosphatase SHP1 
was capable of replacing SHP2 in mediating inhibition (Celis-Gutierrez et al., 2019; Rota et al., 
2018). The relative importance of SHP1 and SHP2 for PD1 function in Tfh cells remains to be 
determined. Another set of recent observations has shown the existence of cis-interactions 
between PD-1/PD-L1 and PD-L1/CD80 on dendritic cells (Sugiura et al., 2019). Since B cells 
can express PD-1 and CD80 (Good-Jacobson et al., 2010), it may be the case that not all PD-L1 
molecules expressed on GC B cells are capable of engaging with PD-1 on Tfh cells to restrain 
their TCR signaling.  
The heterogeneity of PD-1+ T cells in FL and the role of PD-1 in restraining Tfh cell help to GC 
B cells may provide an explanation for the modest effects of PD-1 blockade in FL. If the 
majority of PD-1+ T cells in the FL microenvironment are exhausted CD8+ and CD4+ T cells that 
are failing to perform cytotoxic or immune priming functions, we would hypothesize that FL 
patients would likely have good clinical responses to anti-PD-1 therapy. However, if PD-1+ Tfh 
cells are present in nearly all FL microenvironments, we would hypothesize that blocking PD-1 
in Tfh cells would increase helper signals to FL B cells and lead to poor clinical responses. In 
agreement with the diversity of PD-1+ T cells, while FL clinical responses to PD-1 have only 
been effective in a third of patients, in classical Hodgkin’s lymphoma nearly 90% of patients 
exhibit a response (Mulder et al., 2019; Xu-Monette et al., 2019). This suggests that additional 
immunotherapy approaches that do not unleash Tfh cell helper signals need to be tested in FL, 
such as CD47 blockade, where combination therapy with rituximab has shown a response in 
70% of patients in a small clinical trial (Mulder et al., 2019). CD47 is present on GC B cells and 
and is often upregulated on DLBCL and FL cells (Chao et al., 2010). CD47 binds SIRPα, an 
ITIM containing inhibitory receptor that is expressed on myeloid cells, transmitting an anti-
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phagocytic ‘don’t eat me signal’. Blockade of CD47 maybe an approach to enhance rituximab 
mediated ADCC. SIRPa is not expressed on T cells and therefore blocking antibodies to CD47 
are unlikely to lead to augmented Tfh cell responses. 
ICOS – ICOSL  
ICOS, or inducible T cell co-stimulator, is required for Tfh cell differentiation and 
maintenance (Wan et al., 2019). ICOS, which signals through PI3K, is the dominant co-
stimulatory molecule for Tfh cells and it functions analogously to CD28 once T cells are in the 
GC (Wan et al., 2019; Weber et al., 2015). ICOSL is not known to signal and is downregulated 
on GC B cells compared to follicular B cells. However, ICOSL is upregulated after CD40 
signaling on GC B cells, suggesting that GC B cells that have received the most T cell help enter 
into a positive feedback loop that amplifies this help. Indeed, when ICOSL-high cells versus -
low cells were analyzed for high affinity NP-binding mutations, the highest ICOSL expressing 
GC B cells had increased high affinity mutations. When Tfh cells were stimulated in vitro with 
activating antibodies to CD3 and ICOS, Tfh cells increased their mobilization of CD40L to the T 
cell surface compared to cells activated by anti-CD3 alone, suggesting ICOS signaling enhances 
T cell helper signals to GC B cells (Liu et al., 2014; Wan et al., 2019). While in a competitive 
setting with WT cells, ICOSL-deficient GC B cells formed brief immune synapses with 
decreased surface area of engagement with Tfh cells (Liu et al., 2014; Wan et al., 2019). 
Together these data suggest that ICOSL expression on GC B cells is crucial for positive selection 
by ICOS-expressing Tfh cells.  
Surprisingly, increases in ICOSL expression have not been reported in GC B cell 
lymphomas. However, ICOSL is more highly expressed in GCB-DLBCL compared to ABC-
DLBCL, suggesting ICOSL may be maintained and beneficial in a more GC-like lymphoma 
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microenvironment (Xu-Monette et al., 2016). Although ICOSL transcripts were expressed highly 
in FL cells compared to a B cell line, ICOSL protein was not detected on FL cells in sections. 
Despite this, ICOS has been shown to be highly expressed on FL T cells and specifically on a 
subset of CD25+CXCR5+PD-1+ CD4+ T cells (Le et al., 2016). While Le et al. suggested that 
ICOS is defining a Treg population that is directly suppressing FL B cells through in vitro 
experiments, it has also been shown that ICOS expressing CD4+ T cells in the FL 
microenvironment are IL4-expressing non-regulatory Tfh cells (Ame-Thomas et al., 2012). 
Further study on the role of ICOS-ICOSL signaling in GC lymphomas is needed. 
 
FasL – Fas  
GC B cells are known to be intrinsically prone to cell death given their low expression of 
Bcl-2. Another feature that poises the cells for apoptosis is their high expression of the cell death 
receptor Fas. Fas is a TNFRSF molecule that, upon engagement by FasL, initiates the death 
inducing signaling complex, leading to Caspase-8 activation and apoptosis (Koncz and Hueber, 
2012). Fas is selectively lost in a number of GC-derived lymphomas, as well as antibody driven 
autoimmune diseases. Fas mutations are found in GCB-DLBCL and in some cases of FL and 
transformed FL (Lossos and Gascoyne, 2011; Schmitz et al., 2018). Fas mutations likely arise 
during the GC response and can lead to dominant negative mutations in the death domain or loss 
of expression (Müschen et al., 2002). In autoimmune lymphoproliferative syndrome (ALPS), 
patients with mutations in the Fas death domain have a 14-fold increased likelihood in 
developing non-Hodgkin B cell lymphomas later in life (Straus et al., 2001). Interestingly, 
healthy family members of ALPS patients that have Fas mutations are at increased risk of 
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lymphomagenesis likely due to their accumulation of somatic hypermutations during GC 
responses (Bride and Teachey, 2017).   
In mice, Fas has varying impacts on GC size and B cell affinity maturation. Fas is highly 
expressed on activated and GC B cells. A Fas mutation in the mouse called lpr leads to 
lymphoproliferation and autoimmunity, yet normal sized peak GC responses after acute 
immunization. However, while wild-type GCs begin to contract three weeks post immunization 
Fas-deficient GCs are maintained (Takahashi et al., 2001). In another study, conditional deletion 
of Fas in class-switched B cells was sufficient to lead to increased GC B cell responses (Hao et 
al., 2008). Although FasL transcript was increased in activated T cells and presumably present 
on Tfh cells (Kondo et al., 1997), FasL is difficult to stain for and it has yet to be shown that Tfh 
cells can negatively select GC B cells through FasL. In addition to the elusive source of FasL in 
the GC, contradictory results have been reported for the role of Fas in the GC. Loss of Fas in GC 
B cells led to increased somatic hypermutation, loss of antigen reactivity, and preferential 
differentiation into plasma cells late in the response in a more recent study (Butt et al., 2015). 
Together, these data are inconclusive on whether Fas is a crucial negative regulator of ongoing 
GC responses, but suggest Fas is necessary for the proper contraction of the late GC response 
and suppression of lymphomagenesis. In a setting in which the intrinsic mitochondrial sensitivity 
to cell death is askew, such as in t(14;18) GC B cells, Fas may play a heightened role in 
maintaining stringent GC B cell selection. Such a role has been demonstrated in the setting of c-
Myc overexpression (Totten et al., 2014).  
Due to the downregulation of Fas and its apoptosis promoting signaling in many GC-
derived lymphomas, it is not straightforward to consider how FasL-Fas signaling might be 
restored. One group has suggested that CD74 (the invariant chain) might be a regulator of Fas 
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signaling and that an anti-CD74 antibody, milatuzumab, might act to enhance Fas mediated cell 
death (Berkova et al., 2009), though other mechanisms of anti-CD74 action are likely. Another 
approach might be to inhibit NFκB signaling, which provides resistance to extrinsic cell death 
signaling through a Nedd8-activating inhibitor called Pevonedistat (Paiva et al., 2017). It remains 
to be determined how Fas-mediated cell death can best be enhanced as a treatment for 
lymphomagenesis.  
 
SAP – SLAMF 
Signaling lymphocytic activation molecule (SLAM)-associated protein or SAP (encoded 
by SH2D1A) is a T cell signaling molecule that is mutated or lost in patients with X-linked 
lymphoproliferative (XLP) syndrome (Engel et al., 2003). SAP is composed of a single SH2 
domain and its functions include blocking the recruitment of SHP1 and SHP2 to SLAM proteins. 
SLAM family members are homotypic adhesion receptors that are involved in the formation of 
immune synapses between T and B cells, with SLAMF6 (Ly108) and SLAMF5 (CD84) being 
most important. XLP is thought to arise because NK and CD8+ T cells in SAP-deficient patients 
are ineffective in killing EBV-infected B cells due to exaggerated negative signaling via SLAM-
family proteins. As well as an extreme susceptibility to EBV infection, patients harboring 
SH2D1A mutations have a 200-fold increased risk in developing lymphoma compared to the 
normal population and 30% have an extranodal BL type presentation in the ileum. XLP patients 
have not been reported to have increases in other types of GC-derived lymphomas (Fouquet et 
al., 2018).  
In the mouse, loss of SAP prevents T cells from forming stable conjugates with B cells, 
but not other APCs (Qi et al., 2008). Despite the relatively normal expression of helper 
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molecules, SAP-deficient Tfh cells are altered in their ability to engage GC B cells because 
SLAMF6 and SLAMF5 send inhibitory signals into SAP-deficient T cells, and as a result the GC 
response fails. The importance of SAP in Tfh cell function in supporting GC cells might explain 
why XLP patients do not have an increased incidence of non-EBV associated GC lymphomas. In 
this regard, it is interesting to consider that a lack of B cell killing ability might be expected to 
have a similar effect to loss of b2m or LFA3/CD58, which are common mutations in GC-derived 
lymphomas (Basso and Dalla-Favera, 2015); that SAP-deficiency doesn’t may reflect the need 
for Tfh cells to be able to provide positive signals during lymphomagenesis. While the negative 
role of SLAM family molecules is clearly evident when SAP is lacking, the physiological role of 
SLAM molecules in SAP replete T cells is less clear. SLAM signaling can contribute to Tfh cell 
IL-4 production (Yusuf et al., 2010) though recent analysis of mice lacking all SLAM family 
members did not reveal an essential role for these molecules in the GC response (Huang et al., 
2016). More studies of these SLAM-family deficient mice may help reveal how these molecules 
influence events necessary for antibody diversification and affinity maturation in GCs (Cannons 
et al., 2010).  
 
Tfh cell derived lymphomas 
In additional to GC B cell derived lymphomas, two types of Tfh cell-derived lymphomas, 
angioimmunoblastic T cell lymphoma (AITL) and Tfh-type peripheral T cell lymphoma (Tfh-
PTCL), originate from the GC reaction. Tfh lymphomas frequently maintain a GC 
microenvironment and around half maintain EBV+ B cells and clonal outgrowths of blasting B 
cells in the tumor microenvironment (Schmitz and de Leval, 2016). A case study reported 
depletion of B cells using rituximab combined with chemotherapy was a successful treatment for 
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a relapsed AITL patient with EBV reactivation (Kasahara et al., 2013) making it important to 
determine how broadly these T lymphomas depend on B cells. Tfh-derived lymphomas are 
characterized by epigenetic modifications and often have inactivating mutations in TET2 and 
DNMT2 and activating mutations in IDH2. Additionally, several TCR-related signaling genes are 
mutated and activate the pathway. In 60-70% of AITL and Tfh-PTCL cases, RHOA harbors a 
G17V function altering mutation (Butt et al., 2015). This point mutation was sufficient to 
increase Tfh cells and drive an AITL like disease in a Tet2-deficient background in mice (Cortes 
et al., 2018). Additional activating mutations in the TCR signaling pathway, namely PLCG1, 
PIK3CA, VAV, FYN, LCK mutations, are found in both AITL and Tfh-PTCL (Berkova et al., 
2009). In addition to CD28 mutations, a CTLA4-CD28 fusion gene has been discovered. 
transforming an inhibitory signal into an activating signal (Schmitz and de Leval, 2016). These 
data provide further evidence that AITL and Tfh-PTCL cells depend on engaging with antigen 
presenting GC B cells in the tumor microenvironment.  
Given ICOS’s ability to drive Tfh cell differentiation and helper signals to B cells, it is 
not surprising that multiple mechanisms of regulation of ICOS mRNA has been described, such 
as by Roquin and miR-146a (Paiva et al., 2017). It seems reasonable to speculate that the ICOS-
ICOSL positive feedback loop contributes to Tfh cell maintenance in the GC-derived lymphoma 
microenvironment. In a mouse model in which Roquin, a protein that negatively regulates Icos 
mRNA stability, was heterozygously mutated, ICOS expression was increased and Tfh cells and 
GC B cells spontaneously outgrew; when the mice were aged, AITL developed (Ellyard et al., 
2012). Additionally, in a mouse model of AITL driven by RHOA G17V, ICOS was strongly 
upregulated (Engel et al., 2003). Although Roquin mutations were not reported in a small cohort 
of human AITL patients (Auguste et al., 2013), analysis of more patients is needed.  
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An ICOS blocking antibody MEDI 570 is being tested for the treatment of AITL and 
other Tfh-derived lymphomas in humans (Fouquet et al., 2018). Given that Tfh cell-derived 
lymphomas often maintain normal GC architecture, similar to their malignant B cell 
counterparts, it seems likely that blocking this potent positive regulator of GC responses could 
reduce outgrowth in both B and T cell lymphomas.  
The dependence of SAP—SLAMF signaling for Tfh cell interactions with B cells raises 
the possibility that overexpression of SAP, SLAM, SLAMF5, and SLAMF6 could contribute to 
GC lymphomagenesis. While alterations in their expression have not been described in GC-
derived lymphomas, SLAMF molecules are increased in expression in post-GC chronic 
lymphocytic leukemia (CLL) (Fouquet et al., 2018). Additionally, SAP expression is maintained 
in AITL, suggesting productive AITL Tfh cell immune contacts with B cells are beneficial to the 
tumor cells (Qi et al., 2008).  
 
BTLA – HVEM  
As a TNFRSF molecule, HVEM can recruit TRAF2/TRAF5 and signal via NFκB, as 
well as through NIK and STAT3 (Hsu et al., 1997; Shui et al., 2012; Ward-Kavanagh et al., 
2016). Although it is unexpected that a potential NFκB signaling mediator is selectively lost 
during GC B cell lymphomagenesis, HVEM has been found – as will be described in detail in 
Chapter 2 – to be a tumor suppressor in mouse models of lymphomagenesis (Boice et al., 2016; 
Mintz et al., 2019). HVEM has a complex signaling network that can promote reverse signaling 
through HVEM ligands. HVEM’s signaling network is conserved in mouse and human, with the 
exception of one partner (LTα) which only binds human HVEM. HVEM received its name 
Herpes virus entry mediator as it is the receptor for the gD subunit of HSV-1 and HSV-2. HVEM 
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can also bind to two TNFSF members, LIGHT and LTα through its cysteine rich domain 2 
(CRD2). HVEM transmits reverse signals through its two IgSF ligands BTLA and CD160, 
which bind HVEM’s CRD1, as well as a more recently identified synaptic adhesion molecule 
SALM5 (Ward-Kavanagh et al., 2016; Zhu et al., 2016).  
BTLA, also known as B and T lymphocyte attenuator, is the most highly expressed 
HVEM ligand in the GC (Murphy et al., 2006; Sedy et al., 2004). BTLA, an IgSF member, has 
50% amino acid sequence homology between mouse and human. BTLA was shown 
biochemically to recruit the inhibitory phosphatases SHP1 and SHP2 to its cytoplasmic tail 
(Watanabe et al., 2003). While human BTLA has 4 cytoplasmic tyrosines and mouse only has 3, 
they are conserved in their ability to recruit SHP1, SHP2, and Grb-2, but do not recruit SHIP-1 
(Chemnitz et al., 2004; Gavrieli and Murphy, 2006; Watanabe et al., 2003). In antigen-receptor-
BTLA co-crosslinking studies, BTLA directly inhibited CD3ζ phosphorylation in T cells and 
inhibited BCR signaling by regulating Syk and Fyn in B cells (Vendel et al., 2009; Wu et al., 
2007). BTLA is upregulated in Tfh cells compared to naïve CD4+ T cells, and one study has 
suggested BTLA negatively regulates Tfh cell support of GC B cells by restricting IL-21 
production (Chtanova et al., 2004; Kashiwakuma et al., 2010). Although the BTLA-deficient 
TCR transgenic T cells in this model did support a modestly larger GC B cell response, IL-21 is 
a notoriously difficult to stain for cytokine and the study did not determine if IL-21 mRNA was 
elevated, leaving it unclear whether BTLA-mediated inhibition of IL-21 was the key mechanism 
of action of this HVEM ligand in Tfh cells.  
Here we explore the role of HVEM in regulating the GC B cell response. We use mouse 
models to show HVEM acts as an intrinsic negative regulator of GC B cell responses that depend 
on a trans interaction with BTLA-expressing T cells. We find that BTLA modulates the quality 
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of Tfh cell help provided to GC B cells through preformed CD40L surface mobilization. Lastly, 
we show that BTLA expression on Tfh cells regulates Bcl-2-overexpressing GC B cell 
outgrowth.   
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CHAPTER 2: The HVEM-BTLA axis restrains T cell help to germinal center B cells and 
functions as a cell-extrinsic suppressor in lymphomagenesis 
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Summary 
TNF receptor family member HVEM is one of the most frequently mutated surface 
proteins in germinal center (GC) derived B cell lymphomas, yet the role of HVEM in normal 
GCs is unknown. We found that HVEM-deficiency intrinsically increased B cell competitiveness 
during pre-GC and GC responses. The Ig superfamily molecule BTLA was identified as the 
ligand regulating these responses, and B cell-intrinsic signaling via HVEM and BTLA was not 
required. Instead, BTLA signaling into the T cell through SHP1 reduced TCR signaling and the 
amount of preformed CD40L mobilized to the immunological synapse and thus diminished the 
help delivered to B cells. Moreover, T cell-deficiency in BTLA cooperated with B cell Bcl-2-
overexpression in leading to GC B cell outgrowth. These results establish that HVEM restrains 
the T helper signals delivered to B cells in a manner that influences GC selection outcomes, and 
they suggest that BTLA functions as a cell-extrinsic suppressor of GC B cell lymphomagenesis. 
Introduction 
High affinity germinal center (GC)-derived antibodies are crucial for protection from 
many pathogens. During a T cell-dependent response, antigen-reactive B cells are selected for 
entry into the GC by CD4+ T cells. The earliest T cell selection of the B cell occurs at the T-B 
border 1–2 days after antigen exposure. After 3–6 days, T cells residing in the GC, termed T 
follicular helper (Tfh) cells, are required to select GC B cells. Most data favor a model for high 
affinity B cell selection where cells with improved affinity internalize and present more of the 
antigen and win out in receiving more or better-quality T cell help through CD40 ligand 
(CD40L) or other signals (Bannard and Cyster, 2017; Mesin et al., 2016). However, the factors 
beyond MHC class II-peptide amounts that determine the quantity and quality of help delivered 
to GC B cells are incompletely understood. 
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The tumor necrosis factor (TNF) family receptor HVEM (encoded by the gene 
TNFRSF14) is the most highly mutated surface molecule in GC-derived follicular lymphoma 
(FL) and diffuse large B cell lymphoma (DLBCL) (Cheung et al., 2010; Lackraj et al., 2018; 
Launay et al., 2012; Manso et al., 2017; Schmitz et al., 2018). HVEM is expressed in B cells as 
well as several other cell types, and has multiple ligands. Two ligands, LIGHT and LTα3 are 
members of the TNF superfamily, whereas two other ligands, BTLA and CD160 are members of 
the Ig superfamily. BTLA and CD160 bind HVEM’s first cysteine rich domain (CRD1), whereas 
LIGHT binds CRD2 (Ward-Kavanagh et al., 2016). HVEM contains TRAF-binding motifs in its 
cytoplasmic tail and cross-linking of HVEM can lead to downstream signaling via NFκB 
(Cheung et al., 2009b; Hsu et al., 1997; Shui et al., 2012). In addition to acting as a receptor and 
transducing intracellular signals, HVEM can act as a ligand and transmit signals into BTLA-
expressing cells (Sedy et al., 2004).  
BTLA is widely expressed by immune cells, with high expression on B cells, DCs and 
some effector T cells (Murphy et al., 2006). BTLA contains ITIM (immunoreceptor tyrosine-
based inhibition) motifs in its cytoplasmic domain, and can recruit both SH2-domain containing 
tyrosine phosphatases, SHP1 and SHP2, but not SHIP or SAP (Chemnitz et al., 2004; Gavrieli et 
al., 2003; Steinberg et al., 2011; Watanabe et al., 2003). BTLA can negatively regulate both TCR 
and BCR signaling in vitro (Vendel et al., 2009; Wu et al., 2007) and can be recruited to the 
immune cell interface (Owada et al., 2010). BTLA also contains a Grb2 binding site which may 
promote CD8+ T cell cytokine production and proliferation (Ritthipichai et al., 2017; Wakamatsu 
et al., 2013). Therefore, the signaling actions of BTLA may differ between different cell 
populations and need to be defined on a cell-type by cell-type basis. 
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BTLA is a Tfh cell marker, yet its role in these cells is not well defined (Chtanova et al., 
2004; Kashiwakuma et al., 2010; Nurieva et al., 2009). One study found Btla-/- T cells supported 
a slightly greater IgG2a and IgG2b response following OVA immunization (Kashiwakuma et al., 
2010). In a recent study, shRNA targeting of Hvem in a Bcl-2-driven model of FL increased 
lymphomagenesis (Boice et al., 2016). Hematopoietic shRNA targeting of Btla also increased 
lymphomagenesis and it was suggested that this reflected a function of HVEM within B cells 
engaging BTLA in B cells to transmit BTLA-mediated BCR-repressive signals. Whether such 
signals occur in normal GC B cells has been unclear. 
Here we found that HVEM acts to restrain B cell participation in the GC response by 
signaling via BTLA on T cells. HVEM-deficiency provided a proliferative advantage to B cells 
as early as day 3–4 of the response. Interaction of HVEM with BTLA on the T cells decreased 
the TCR signal and the amount of preformed CD40L mobilized to the T cell surface, thereby 
limiting B cell help. Thus, HVEM on B cells restrains T cell help to influence GC selection 
outcomes, and interfering with this regulatory axis provides a competitive advantage in GC B 
cell lymphomagenesis.  
 
Results 
 
HVEM-deficiency increases GC B cell competitiveness  
Hvem (Tnfrsf14) transcripts were expressed at similar levels in follicular and GC B cells 
(Fig. 2.1A) and HVEM protein was present on the surface of both cell types though at lower 
levels on GC B cells (Fig. 2.1B). To test whether HVEM is an intrinsic regulator of GC B cell 
responses, we generated mixed bone marrow (BM) chimeric mice where BM from wild-type 
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(WT) CD45.1 donor mice was mixed with CD45.2 BM from Hvem+/- or Hvem-/- mice. Following 
immunization with sheep red blood cells (SRBC), HVEM-deficient B cells were over-
represented in GCs compared to the follicular compartment (Fig. 2.1C and Fig. S1A). HVEM 
heterozygosity led to an intermediate phenotype (Fig. 2.1C). The participation of Hvem-/- B cells 
in the follicular compartment matched that of developing B cells in the BM (Fig. S1B). HVEM-
deficiency also provided GC B cells with increased competitiveness in chronic GCs in the 
mesenteric LN (mLN) and Peyer’s Patches (PP) (Fig. S1C). Hvem-/- B cells were similarly over-
represented in the light and dark zone of the GC (Fig. S1D). While HVEM-deficiency gave GC 
B cells a competitive advantage in the mixed setting, it did not lead to a significant increase in 
GC size in competitive or non-competitive conditions (Fig. S1E, F). 
To permit tracking of antigen-specific B cells during the GC response, mixed BM 
chimeras were immunized with the haptenated antigen NP-CGG in alum adjuvant. In the GC 
response at day 6–7 after immunization, HVEM-deficient GC B cells were increased in 
frequency compared to the follicular compartment (Fig. 2.1D). Notably, this advantage was more 
pronounced in the non-hapten binding (NP–) GC B cells compared to the NP+ fraction (Fig. 
2.1D). HVEM-deficient GC B cells maintained approximately the same magnitude of advantage 
over the course of the GC response through day 21 (Fig. 2.1D). In full Hvem-/- animals the 
frequency of NP+ GC B cells was similar to WT littermate controls, suggesting there is not a 
baseline repertoire difference (Fig. S1G, H).  
Paired-end RNA sequencing and BCR gene usage analysis through MIXCR (Bolotin et 
al., 2015) at day 11 of the response showed Hvem-/- GC B cells had decreased usage of Iglv1, the 
canonical λ chain expanded during NP responses in C57BL/6 mice, compared to the WT 
competitors (Fig. 2.1E). PCR on sorted GC B cells from mixed BM chimeras was performed to 
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examine the frequency of high affinity mutations in the canonical NP-responding VH186.2 gene 
at days 11–13. When referenced against the WT mixed chimeras, HVEM-deficient GC B cells 
had a decreased stringency in selection for the W33L mutation compared to WT GC B cells in 
the same animal (Fig. 2.1F).   
The SRBC immunized mixed BM chimeras showed an increased frequency of memory B 
cells (Bmem) and plasma cells (PCs) at day 8 (Fig. S1A, I). HVEM-deficiency also increased the 
frequency of NP+ Bmem and PCs at day 7–21 of the NP-CGG response (Fig. S1J). These data 
suggest Bmem and PCs were generated approximately in proportion to the GC cells. 
Additionally, HVEM-deficiency did not affect the frequency of IgG1+ class-switched B cells in 
the GC (Fig. S1K). One mechanism by which HVEM-deficiency could lead to increased GC B 
cell accumulation was by reduced cell death. However, the frequencies of apoptotic HVEM-
deficient and WT GC B cells as measured by active caspase-3 were similar (Fig. S1L). These 
findings led us to consider whether B cell proliferation might be affected. 
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Figure 2.1. HVEM-deficiency increases GC B cell competitiveness  
(A) Quantitative PCR analysis of Hvem (Tnfrsf14) transcript abundance in follicular (Fo) and GC 
B cells, shown relative to Ptprc. (B) Representative flow cytometric analysis of HVEM surface 
expression on Hvem+/+ Fo and GC B cells compared to Hvem-/- cells. (C) Contribution of 
Hvem+/+, Hvem+/-, Hvem-/- CD45.2 cells to Fo and GC populations in spleen of mixed BM 
chimeras made with ~30% CD45.2 and ~70% WT CD45.1 BM at day 8 after SRBC 
immunization. Data are representative of >3 independent experiments. (D) Ratio of Hvem+/+ or 
Hvem-/- NP+ or NP- CD45.2 GC to total CD45.2 Fo B cells in mixed BM chimeras after NP-CGG 
alum immunization at days 6–21 of the splenic response. Data are shown as ratios to simplify 
varied mixing of ~20-50% CD45.2 and ~80-50% CD45.1 BM across experiments. Data are 
pooled from >5 experiments. (E) MIXCR BCR repertoire analysis of Ig light chain V gene usage 
from paired-end bulk RNA sequencing on FACS sorted GC B cells from Hvem-/- CD45.2 (n=3) 
and WT CD45.1 (n=3) from the same mixed BM chimeras at day 11 after NP-CGG alum 
immunization, ±SD shown. (F) Frequency of W33L mutations in the VH186.2 heavy chain from 
sorted CD45.2 Hvem-/- or Hvem+/+ and respective CD45.1 WT GC B cells at days 11–13 after 
NP-CGG immunization of mixed BM chimeras. Data are pooled from 5 experiments. *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001. Unpaired Student’s t test, A, C, D. Chi-Squared and 
Fischer’s exact test, E, F. Bars indicate mean ±SD. See also Figure S1. 
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HVEM-deficiency provides the earliest GC B cells with a proliferation advantage 
To determine if HVEM-deficiency increased B cell entry into the GC, we crossed the 
Hvem-/- mouse line to the Hy10 mouse line, which has a BCR specific for hen egg lysozyme 
(HEL). To test if Hvem-/- B cells proliferate more than their competitors during the early 
response, Hvem-/- and WT Hy10 B cell mixes were labeled with cell trace violet (CTV) and co-
transferred with OVA-specific OT-II CD4+ T cells into WT hosts and immunized with HEL-
OVA or a lower affinity antigen, DEL-OVA (Fig. 2.2A). At day 2 the amount of proliferation in 
each group was similar, but by day 3, Hvem-/- Hy10 B cells had an increased frequency of cells 
that had divided greater than 4 times, as measured by the increase in CTVlo cells (Fig. 2.2B, C). 
The response to high and low affinity forms of the antigen was similar (Fig. 2.2C). When 
referenced against the proliferation rates of cells in the control mixed transfers it was evident that 
the major difference was the lower proliferation rate of the WT cells that were in competition 
with the HVEM-deficient cells (Fig. 2.2C).  At day 4.5–5 after immunization, when both 
plasmablasts (PB) and GC B cells could be clearly identified by flow cytometry (Fig. S2A), 
Hvem-/- Hy10 B cells had an increased frequency in the GC compartment compared to WT 
competitors (Fig. 2.2D). There was also an increase in the PB compartment though this effect 
was often not as marked as observed for the GC B cells in the same animals (Fig. 2.2D). These 
data suggest that HVEM-deficiency reveals itself in a competitive environment by allowing 
Hvem-/- B cells to outcompete the ability of WT B cells to proliferate.  
 
Loss of HVEM in an ongoing GC provides B cells with a competitive advantage  
Tfh cells are involved in supporting the early steps in GC induction as well as the mature 
GC response. To test if the growth advantage of HVEM-deficient B cells required Tfh cells, we 
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transferred Hvem-/- and WT Hy10 B cell mixes into Tfh cell-deficient Bcl6 f/f Cd4Cre hosts. At 
days 5–7 after immunization with an intermediate affinity HEL conjugated to SRBC, 2x-HEL-
SRBC, Hy10 B cells expanded in both control and Bcl6f/f Cd4Cre hosts (Fig. S2B). While Hvem-/- 
Hy10 B cells had an increased frequency compared to their WT competitors in control hosts, the 
HVEM-deficient advantage was lost in the Tfh cell-deficient hosts (Fig. 2.2E).  
To determine if HVEM-deficiency provided B cells with a competitive growth advantage 
once the cells were within the GC, we crossed Hvem floxed animals to the inducible GC Cre 
line, S1pr2ERT2Cre, and to tdTomatof/f reporter animals. We then made mixed BM chimeras with 
the Hvem floxed line and respective controls, immunized with NP-CGG, and treated with 
tamoxifen at day 3 to activate Cre in S1pr2+ GC B cells (Fig. 2.2F). We found that >70-80% of 
CD45.2 GC B cells were expressing tdTomato and HVEM surface expression was decreased to 
nearly Hvem-/- levels in the GC, but was unchanged in follicular B cells (Fig. S2C, S2D). 
Importantly, Hvemf/f S1pr2ERT2Cre GC B cells had a 30-50% increase in their representation 
compared to their frequency amongst follicular B cells whereas the control Hvemf/f Cre– and 
Hvem+/+ Cre+ GC B cells did not increase in their representation (Fig. 2.2G). A 1 hr EdU labeling 
analysis showed that a slightly greater fraction of HVEM-deficient than internal control GC B 
cells were in cell cycle (Fig. 2.2H). As another way to test the impact of HVEM loss at the GC 
stage, we crossed Hvem floxed animals to the Cγ1Cre line, which acts earlier in the response and 
avoids the need for tamoxifen. In mixed BM chimeras, Hvemf/fCγ1Cre GC B cells had a growth 
advantage over the control GC B cells (Fig. S2E, F). These findings indicate HVEM has a 
restraining influence on B cells during GC seeding and within the GC. 
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Figure 2.2. HVEM-deficiency provides B cells with a proliferation advantage early in the 
response and within the GC  
(A)  Experimental scheme and timeline for experiments in A-D. (B) Representative cell trace 
violet (CTV) dilution at 48 and 72 hr of Hy10 B cells compared to co-transferred WT Hy10 B 
cells after DEL-OVA. Hvem+/+ or Hvem-/- Hy10 in red and WT mixing partner (Control) in blue. 
(C) Frequency of CTV-diluted (defined as >3 divisions at 48 hr and >4 divisions at 72 hr) Hy10 
B cells compared to their WT mixing controls. Grey circles indicate HEL-OVA and red circles 
DEL-OVA immunization. Data are pooled from 3 experiments. (D) Ratio of the frequency of 
GFP+ HEL+ GC B cells or plasmablasts (PB) at days 4.5–5 after HEL-OVA immunization to 
pre-transfer frequency of GFP+ HEL+ B cells. Data are pooled from 3 experiments, with pre-
transfer mixtures of GFP+ cells ~20-60%. (E) Mixed Hy10 transfer with endogenous T cell 
response into Bcl6f/f Cd4Cre hosts and 2x-HEL SRBC immunization. Ratio of the frequency of 
CD45.1/2 Hvem+/+ or Hvem-/- Hy10 to pre-transfer frequency. Tfh cell-deficient (Bcl6f/f Cd4Cre) 
and controls hosts were analyzed at days 5–7. Data are pooled from 3 experiments. (F) 
Experimental scheme and timeline for experiments in F-G. (G) Frequency of CD45.2 Fo and GC 
B cells in the tamoxifen treated mixed BM chimeras. Data are pooled from 3 experiments and 
include chimeras with 10-60% CD45.2 Fo B cells. (H) Frequency of EdU+ IgDloEphrinB1+ GC 
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B cells in Hvem+/+ and Hvem-/- mixed BM chimeras immunized with NP-CGG. Animals were 
treated with EdU 1 hr before analysis at days 6–7 (black circles) and day 21 (red circles). Data 
are pooled from 3 experiments. *P<0.05, **P<0.01,  ***P<0.001, ****P<0.0001. Unpaired two-
tailed Student’s t test, C-E, G. Paired two-tailed Student’s t test, H. See also Figure S2. 
 
HVEM signaling intrinsic to the B cell is not required for GC B cell suppression 
To test whether HVEM signaling into the B cell was required for HVEM-mediated 
restraint of the GC response, we used a gain-of-function approach. BM chimeric mice were 
generated using BM that had been transduced with MSCV-Thy1.1 retrovirus encoding full 
length or mutated forms of Hvem and the reconstituted mice were immunized with SRBC (Fig. 
2.3A-C). Overexpression of WT HVEM suppressed the representation of Thy1.1 reporter+ GC B 
cells by 50% compared to follicular B cells while overexpression of an empty vector (EV) did 
not alter Thy1.1+ B cell participation in the GC (Fig. 2.3C, D).  
To determine if loss of HVEM’s ability to recruit TRAF2/5 impacted GC B cell 
participation, we introduced a point mutation in the HVEM cytoplasmic tail, E271A, that is 
known to disrupt TRAF recruitment (Hsu et al., 1997). This mutant form of HVEM was 
expressed on the cell surface and repressed B cell participation in the GC to the same extent as 
WT HVEM (Fig. 2.3B-D). To rule out signaling via other parts of the HVEM cytoplasmic tail, a 
mutant was generated harboring a stop codon at position 235 (Δ235) immediately after the 
transmembrane domain. This construct suppressed B cell participation in the GC to a similar 
extent as WT (Fig. 2.3B-D). The Δ235 mutant also restrained B cell participation in the GC 
when expressed in Hvem-/- cells (Fig. 2.3E). These data demonstrate that HVEM’s intrinsic 
signaling into the B cell is not required for its ability to restrain B cell participation in the GC 
response.  
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A point mutation at Y61A within HVEM’s CRD1 disrupts binding to BTLA and CD160 
(Cheung et al., 2009a). Unlike WT HVEM, Y61A HVEM failed to reduce the participation of 
transduced B cells in the GC response, suggesting that HVEM’s ability to bind a ligand through 
CRD1 is required (Fig. 2.3F, G).  
 
Figure 2.3. HVEM signaling intrinsic to the B cell is not required for GC B cell suppression 
(A) Experimental scheme and timeline for experiments in B-G. (B) Model of HVEM WT, 
E271A (TRAF2/5 binding mutant), Δ235 (cytoplasmic tail truncation), Y61A (CRD1 binding 
mutant). (C) Representative flow cytometric analysis of HVEM and Thy1.1 expression on Fo 
and GC B cells in empty vector (EV), HVEM WT, E271A and Δ235 transduced BM chimeras. 
(D) Frequency of Thy1.1+ cells in GC compared to Fo in Hvem+/+ BM chimeras in splenic 
response. Data are pooled from 3 experiments. (E) Frequency of Thy1.1+ cells in GC compared 
to Fo in Hvem-/- BM chimeras in splenic response. Data are pooled from 2 experiments. (F) 
Representative flow cytometric analysis of HVEM and Thy1.1 expression on Fo and GC B cells 
in HVEM Y61A transduced BM chimeras. (G) Frequency of Thy1.1+ cells in GC compared to 
Fo in Hvem-/- BM in pLN response. Data are pooled from 2 experiments. *P<0.05, **P<0.01, 
***<P0.001, ****P<0.0001. Ordinary One-Way Anova with Bonferroni’s multiple comparisons 
test, D, E, G. 
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Figure 3. HVEM Signaling Intrinsic to the B Cell Is Not Required for GC B Cell Suppression
(A) Experimental scheme and timeline for experiments in (B)–(G).
(B) Model of HVEM WT, E271A (TRAF2/5 binding mutant), D235 (truncation of cytoplasmic tail), and Y61A (CRD1 binding mutant).
(C) Representative flow-cytometric analysis of HVEM and Thy1.1 expression on Fo and GCB cells in BM chimeras transduced with empty vector (EV), HVEMWT,
HVEM E271A, and HVEM D235.
(D) Frequency of Thy1.1+ cells in GC versus Fo in Hvem+/+ BM-reconstituted chimeras. Data are pooled from three experiments.
(E) Frequency of Thy1.1+ cells in GC versus Fo in Hvem!/! BM-reconstituted chimeras. Data are pooled from two experiments.
(F) Representative flow-cytometric analysis of HVEM and Thy1.1 expression on Fo and GC B cells in HVEM-Y61A-transduced BM chimeras.
(G) Frequency of Thy1.1+ cells in GC versus Fo in Hvem!/! BM in pLN response. Data are pooled from two experiments.
Ordinary one-way ANOVA with Bonferroni’s multiple-comparisons test (D, E, and G): *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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BTLA on CD4+ T cells is required for HVEM-deficient GC B cell competitiveness 
Since BTLA is an inhibitory receptor highly expressed in the GC on both B cells and T 
cells (Fig. 2.4A), we tested if BTLA is required for HVEM’s suppressive ability. When HVEM 
was overexpressed in Btla-/- BM chimeric mice, Thy1.1 reporter+ GC B cells participated in the 
GC at the same frequency as in follicular B cells (Fig. 2.4B). This finding contrasted with the 
repressive effect of HVEM overexpression on B cells in WT BM chimeric mice (Fig. 2.3D) and 
suggested that BTLA was the relevant ligand for HVEM’s ability to suppress participation in the 
GC.  
In vitro studies have shown that BTLA in B cells can inhibit BCR signaling and it has 
been suggested that HVEM-BTLA can interact in cis within the same cell (Cheung et al., 2009a; 
Vendel et al., 2009), and a role for such cis interactions has been invoked to explain findings in a 
mouse FL model (Boice et al., 2016; Huet et al., 2018; Verdière et al., 2018). If the actions of 
HVEM in restraining B cell participation in the GC were dependent on cis engagement with 
BTLA, it would be predicted that B cells lacking BTLA would have a GC growth advantage 
similar to that observed for HVEM-deficient cells. Analysis of mice reconstituted with a mixture 
of WT and Btla-/- BM showed that cell intrinsic loss of BTLA did not alter the frequency of B 
cells in the GC (Fig. 2.4C). Similar results were obtained when mixed BM chimeras were made 
using BM from Btlaf/f Mb1Cre mice that selectively lack BTLA in B cells (Fig. S3A, B).  
To determine if BTLA on bystander B cells was acting in trans to influence antigen-
reactive B cells, Hvem-/- and WT Hy10 B cell mixes were transferred into Btlaf/f Mb1Cre or 
control hosts that were then immunized with 2x-HEL-SRBC (Fig. 2.4D). Hvem-/- Hy10 B cells 
maintained their growth advantage in the BTLA-B cell deficient hosts, suggesting bystander B 
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cells were not the cellular source of BTLA for HVEM-mediated suppression of GC B cell 
participation (Fig. 2.4E). 
BTLA is a defining marker on Tfh cells compared to other CD4+ T cells (Fig. 4A) 
(Chtanova et al., 2004; Kashiwakuma et al., 2010; Nurieva et al., 2009). To test if HVEM-
deficient GC B cell competitiveness required BTLA-expressing T cells, Hvem-/- and WT Hy10 B 
cell mixes were transferred into Btlaf/f Cd4Cre hosts that lacked BTLA in all T cells (Fig. S3A). 
The hosts were immunized with 2x-HEL-SRBC and analyzed at day 3–6 of the response (Fig. 
2.4D). The Hvem-/- Hy10 GC B cell growth advantage was abrogated in BTLA-T cell deficient 
mice at all timepoints analyzed (Fig. 2.4F and Fig. S3C). Tfh cells were present at similar 
frequencies in both types of recipient animal (Fig. S3D, E) and the frequency of HEL+ 
responding B cells was also similar (Fig. S3F). BTLA was upregulated in T cells between day 2 
and day 3 of the response (Fig. S3G, H), kinetics that matched the timing of when HVEM began 
to regulate the B cell proliferative response (Fig. 2.2B). These data indicate that BTLA-
expressing T cells are required for the Hvem-/- GC B cell competitive advantage. 
A previous study reported that BTLA deficiency led to increased IL-21 production by in 
vitro generated and restimulated Tfh cells (Kashiwakuma et al., 2010). However, when Tfh cells 
were generated in vivo, we did not observe a difference in Il21 expression between BTLA-
deficient and WT Tfh cells from the same animals (Fig. S3I). 
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Figure 2.4. BTLA on T cells restrains GC B cell competitiveness 
(A) Flow cytometric analysis of BTLA expression on B cells (left) and CD4+ T cells (right) 
compared to Btla-/-. (B) HVEM overexpression Btla-/- BM chimeras were made by transducing 
empty vector (EV) or HVEM (WT) MSCV-Thy1.1 constructs into Btla-/- BM and reconstituting 
CD4-depleted hosts. Chimeras were then immunized with SRBC and the participation of 
Thy1.1+ cells in the GC compared to Fo B cell compartments was determined. (C) Contribution 
of Btla+/+ or Btla-/- CD45.2 cells to Fo and GC populations in spleen of mixed BM chimeras 
made with ~40% of CD45.2 and ~60% of WT CD45.1 at day 7 after SRBC immunization. (D) 
Experimental scheme and timeline for experiments in E, F.  (E) Ratio of the frequency of 
CD45.1/2 Hvem-/- HEL+ B cells in BTLA-B cell deficient (Btlaf/f Mb1Cre) hosts at day 5 to the 
pre-transfer frequency. (F) Ratio of CD45.1/2 Hvem+/+ or Hvem-/- HEL+ GC B cells to pre-
transfer mix in BTLA-T cell deficient (Btlaf/f Cd4Cre) hosts at day 3–6. Data pooled from 4 
experiments. *P<0.05, **P<0.01, ***<P0.001, ****P<0.0001. Unpaired two-tailed Student’s t 
test, B, C, E, F. See also Figure S3. 
 
BTLA-HVEM at the immunological synapse recruits SHP1 to inhibit signaling in Tfh cells 
To determine if BTLA can alter CD4+ T cell signaling at the immunological synapse 
when engaging HVEM, we turned to the well-established supported lipid bilayer model (Dustin 
et al., 2007). Human CD4+ T cell blasts were transfected with BTLA to mimic the surface 
expression in Tfh cells (Fig. S4A) and settled on supported lipid bilayers containing anti-CD3 
BA C
0 103 104 105
0
20
40
60
80
100
0 103 104 105
0
20
40
60
80
100 WT Fo
WT GC
KO GC
KO Fo
WT T
WT Tfh
KO Tfh
KO T
BTLA
%
 o
f m
ax
E
Transfer Hy10 B cells:
HVEM -/-  or +/+ CD45.1/2 (50%) :
WT CD45.1 (50%)
Immunize i.p.
2x-HEL SRBC
Flow cytometry 
analysis (spleen)
d -1 d 0 d 3-6Host: BTLA f/f 
Mb1-Cre or CD4-Cre
D
F
EV WT
0.0
0.5
1.0
1.5
Th
y1
.1
 G
C
B/
Th
y1
.1
 F
oB
ns
HVEM:
f/f 
-
f/f
+
0.0
0.5
1.0
1.5
C
D
45
.1
/2
 o
f H
EL
+ 
/
Pr
e-
tx
ns
BTLA:
Mb1-Cre:
WT
f/f 
-
WT
f/f
+
KO
f/f 
-
KO
f/f
+
WT
f/f 
-
WT
f/f
+
KO
f/f 
-
KO
f/f
+
WT
f/f 
-
WT
f/f
+
KO
f/f 
-
KO
f/f
+
0.0
0.5
1.0
1.5
2.0
C
D
45
.1
/2
 o
f H
EL
+G
C
 /
Pr
e-
tx
***
*
HVEM:
BTLA:
CD4-Cre:
Day:
ns
ns
***
ns
3 4 5-6
Fo GC Fo GC
0
20
40
60
80
%
 C
D
45
.2
B cell:
BTLA: WT KO
nsnsBTLA KO BM
 39 
(UCHT1) and ICAM1 for 15 min before fixation. When HVEM was added to the bilayers, 
BTLA and HVEM were recruited to the synapse, forming a ring around the central synaptic cleft 
in cases where a stable synapse was formed (Fig. 2.5A). In the presence of HVEM, there was a 
shift in interface organization from the stable synapse to the motile kinapse state (Mayya et al., 
2018) where the TCR cluster is at one pole of the interface (Fig. 2.5B and Fig. S4B). 
BTLA has been shown to recruit SHP1 and SHP2 biochemically through Y257 and Y282 
(Gavrieli et al., 2003; Watanabe et al., 2003). BTLA demonstrated a strong colocalization with 
SHP1 at the synapse while SHP2 did not preferentially co-localize (Fig. 2.5C-F). When the 
CD4+ T cells blasts were transfected with a BTLA Y257F/Y282F mutant, SHP1 colocalization 
was diminished and SHP2 was unchanged (Fig. 2.5C-F). The incomplete effect on SHP1 
recruitment likely reflects the activity of endogenous BTLA in the blasts. These results are in 
contrast to the PD-1 molecule that colocalizes preferentially with SHP2 at the synapse (Fig. S4C-
F). 
In accord with SHP1 recruitment, inclusion of HVEM in the bilayer inhibited the amount 
of signaling downstream of the TCR as measured by pZAP70 and pPKCθ (Fig. 2.5G-J and Fig. 
S4G-H). This observation was made for both BTLA-transfected CD4+ T cells and human tonsil-
derived Tfh cells (Fig. 2.5G-J and Fig. S4G-H). Inclusion of the CD28 ligand CD80 in the 
bilayer led to an elevated amount of signaling and HVEM continued to reduce, in most cases 
significantly, the extent of ZAP70 and PKCθ activation (Fig. 2.5G-J and Fig. S4G-H). These 
data suggest that HVEM engagement of BTLA inhibits T cell activation through SHP1 at the 
immunological synapse. 
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Figure 2.5. BTLA-HVEM at the immunological synapse recruits SHP1 to inhibit signaling 
in Tfh cells 
(A) Example TIRF images of BTLA-transfected human CD4+ T cell blasts on supported lipid 
bilayers containing anti-CD3, ICAM1 and, where indicated, HVEM and/or CD80. Staining for 
CD3 (UCHT1), ICAM1 and BTLA is shown. (B) Quantification of kinapse versus synapse state 
of cells imaged as in A. (C) Model of human BTLA binding mutant Y257F/Y282F designed to 
disrupt SHP1/2 recruitment to the last 2 of 4 cytosolic tyrosines. (D) Representative images of 
SHP1 and SHP2 recruitment to the synapse in relation to WT or mutant BTLA. (E, F) 
Quantification of SHP1 (E) and SHP2 (F) colocalization with WT or mutant BTLA with or 
without HVEM in the bilayer using Pearson’s colocalization coefficient (PCC). (G) 
Representative images of pZAP70 in human Tfh cells in relation to HVEM in the bilayer after 15 
min on the bilayer with standardized Lookup Table (LUT) across panels so fluorescence can be 
Figure 5. BTLA-HVEM at the Immunological Synapse Recruits SHP1 to Inhibit Signaling in Tfh Cells
(A) Example total internal reflection fluorescence (TIRF) and interference reflection microscopy (IRM) images of BTLA-transfected human CD4+ T cell blasts on
supported lipid bilayers containing anti-CD3, ICAM1, and where indicated, HVEM and/or CD80. Staining for CD3 (UCHT1), ICAM1, and BTLA is shown.
(B) Quantification of kinapse versus synapse state of cells imaged as in (A).
(C) Model of human BTLA binding mutant Y257F/Y282F, designed to disrupt SHP1 and SHP2 recruitment to the last two of four cytosolic tyrosines.
(D) Representative images of SHP1 and SHP2 recruitment to the synapse in relation to that of WT or mutant BTLA.
(E and F) Quantification of SHP1 (E) and SHP2 (F) colocalization with WT or mutant BTLA with or without HVEM in the bilayer as determined with Pearson’s
colocalization coefficient.
(G) Representative images of pZAP70 in human Tfh cells in relation to HVEM in the bilayer after 15 min on the bilayer; a standardized lookup table (LUT) is shown
across panels so fluorescence can be directly compared.
(H) Relative amount of pZAP70 in BTLA-transfected CD4+ T cell blasts and Tfh cells with or without HVEM and CD80 in the bilayer (normalized to the condition
without HVEM and CD80).
(I) Representative images of pPKCq in human Tfh cells in relation to HVEM in the bilayer after 15 min on the bilayer; a standardized LUT is shown across panels so
fluorescence can be directly compared.
(J) Relative amo nt of pPKCq in BTLA-transfected CD4+ T cell blasts and Tfh cells with or without HVEM and CD80 in the bilayer (normalized to the condition
without HVEM and CD80). Data are pooled from three independent donors and experiments.
Scale bars: 5 mm. Chi-square and Fischer’s exact tests (B) or Mann-Whitney test (E, F, H, and J): *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also
Figure S4.
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directly compared. (H) Relative amount of pZAP70 in BTLA-transfected CD4+ T cell blasts and 
Tfh cells with or without HVEM and CD80 in the bilayer normalized to no HVEM no CD80 
condition. (I) Representative images of pPKCq in human Tfh cells in relation to HVEM in the 
bilayer after 15 min on the bilayer with standardized LUT across panels so fluorescence can be 
directly compared. (J) Relative amount of pPKCq in BTLA-transfected CD4+ T cell blasts and 
Tfh cells with or without HVEM and CD80 in the bilayer normalized to no HVEM no CD80 
condition. Data pooled from 3 independent donors and experiments. Scale bars are 5 µm. 
*P<0.05, **P<0.01, ***<P0.001, ****P<0.0001. Chi-squared with Fischer’s exact test, B, 
Mann-Whitney test E, F, H, J. See also Figure S4. 
 
BTLA signaling into the T cell through SHP1 is required for HVEM-deficient GC B cell 
competitiveness 
To test if BTLA signaling was restraining the help provided to B cells, we generated a 
mutant mouse line (termed BTLA Y3) that lacks the BTLA cytoplasmic tail (Fig. 2.6A and Fig. 
S5A). Hvem-/- Hy10 spleen cell mixes were then transferred into Btla+/+, Btlay3/y3, Btla-/- hosts, 
and the mice were immunized with 2x-HEL-SRBC and analyzed at day 5. Btlay3/y3 hosts 
abrogated the Hvem-/- Hy10 GC B cell competitive advantage, phenocopying Btla-/- hosts (Fig. 
2.6B). BTLA Y3 mutant protein was expressed at reduced levels on the T cell surface, 
comparable to those on Btla+/- Tfh cells (Fig. S5B). To control for possible effects of the reduced 
expression we also performed transfers into Btla+/- recipients. The Hvem-/- B cells showed a 
similar competitive advantage in heterozygous and WT hosts (Fig. 2.6B). These findings provide 
evidence that the BTLA cytoplasmic domain in host T cells is required for HVEM-mediated 
restraint of B cell participation in the GC response. 
To test which of BTLA’s intracellular binding partners in the T cell was restraining the 
signal to HVEM-expressing GC B cells, Hvem-/- and WT Hy10 B cell mixes were transferred 
into Ptpn6fl/fl (SHP1) and Ptpn11fl/fl (SHP2) Cd4Cre or control hosts. Tfh cell frequencies in the 
SHP1 and SHP2 T cell-deficient hosts were comparable in the spleen compared to controls (Fig. 
S5C, D). The Hvem-/- GC B cell competitive advantage was lost in SHP1 T cell-deficient hosts, 
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while it was maintained in the SHP2 T cell-deficient hosts (Fig. 2.6C, D). The frequency of 
HEL-binding B cells in both types of host was comparable to controls (Fig. S5E, F). These data 
suggest that following HVEM engagement, BTLA recruits SHP1 to moderate the activation of 
the T cell and the amount of help provided to the HVEM-expressing B cell.  
 
Figure 2.6. BTLA signaling into the T cell through SHP1 is required for HVEM-deficient 
GC B cell competitiveness 
(A) Model of murine BTLA truncation termed Y3 in which all three cytoplasmic tyrosines have 
been removed. (B) Ratio of Hvem-/- GFP+ HEL+ GC (IgDloFas+) B cells compared to the pre-
transfer mix (~20% Hvem-/- GFP+ Hy10 : ~80% WT CD45.1 Hy10) in Btla+/+, Btla+/-, Btlay3/y3, 
Btla-/-. Data pooled from 2 experiments. (C) Ratio of Hvem+/+ or Hvem-/- GFP+ HEL+ GC B cells 
compared to the pre-transfer mix in Ptpn6f/f (SHP1) control or Cd4Cre hosts. Data pooled from 4 
experiments. (D) Ratio of Hvem+/+ or Hvem-/- GFP+ HEL+ GC B cells compared to the pre-
transfer mix in Ptpn11f/f (SHP2) control or Cd4Cre hosts. Data pooled from 3 experiments. (E) 
Representative flow cytometric analysis of CD40L surface mobilization on OT-II Tfh cells after 
a 30 min incubation with B cells pulsed with a titration of OVA peptide (0-10 µM). (F) CD40L 
expression on OT-II Tfh cells stimulated as in E, normalized to unstimulated Tfh cells. Data 
were immunized with 23-HEL-SRBC and analyzed at day 5.
Btlay3/y3 hosts phenocopied Btla!/! hosts by abrogating the
Hvem!/! Hy10 GC B cell competitive advantage (Figure 6B).
BTLA Y3mutant protein was less expressed on th T cell surface
than on WT Tfh cells (Figure S5B). To control for possible eff cts
of the reduced expression, we also performed transfers into
Btla+/! recipients whose T cell BTLA expression was similar to
that of Btlay3/y3 mice (Figure S5B). The Hvem!/! B cells showed
a similar competitive advantage in BTLA heterozygous and WT
hosts (Figure 6B). These findings provide evidence that the
BTLA cytoplasmic domain in host T cells is required for HVEM-
mediated restraint of B cell participation in the GC response.
To test which of BTLA’s intracellular binding partners in the
T cell restrains the signal to HVEM-expressing GC B cells, we
transferred Hvem!/! and WT Hy10 B cell mixes into Ptpn6fl/fl
(SHP1) and Ptpn11fl/fl (SHP2) Cd4Cre or control hosts. Splenic
Tfh cell frequencies in the SHP1 and SHP2 T-cell-deficient hosts
were similar to those in controls (Figures S5C and S5D). The
Hvem!/! GC B cell competitive advantage was lost in SHP1
T-cell-deficient hosts, whereas it was maintained in SHP2
T-cell-deficient hosts (Figures 6C and 6D). The frequency of
HEL-binding B cells in both host types was comparable to that
in controls (Figures S5E and S5F). These data suggest that after
HVEM engagement, BTLA recruits SHP1 tomoderate the activa-
tion of the T cell and the amount of help provided to the HVEM-
expressing B cell.
HVEM-BTLA Interaction Reduces the Amount of CD40-
CD40L Brought to the Synaptic Interface
For a Tfh cell to provide greater help to HVEM-deficient B cells
than to HVEM-expressing B cells in the same GC microenviron-
ment during interactions that often last only a few minutes, Tfh
cell BTLA most likely has to regulate the mobilization of a pre-
formed mediator. The best defined pre-formed helper factor in
Tfh cells is CD40L (Casamayor-Palleja et al., 1995; Koguchi
et al., 2007; 2012). However, it has been unclear whether the
amount of preformed CD40L displayed on the T cell surface
can be tuned by the strength of the TCR signal. As one approach
to test this, we incubated OVA-specific OT-II Tfh cells for 30 min
with B cells that had been pulsed with a range of OVA-peptide
Figure 6. BTLA Signaling into the T Cell
through SHP1 Is Required for HVEM-Defi-
cient GC B Cell Competitiveness
(A) Model of murine BTLA truncation, termed Y3, in
which all three cytoplasmic tyrosines have been
removed.
(B) Ratio of Hvem!/! GFP+HEL+ GC (IgDloFas+)
B cells to the pre-transfer mix ("20% Hvem!/!
GFP+ Hy10 to "80% WT CD45.1 Hy10) in Btla+/+,
Btla+/!, Btlay3/y3, and Btla!/! hosts. Data are
pooled from two experiments.
(C) Ratio of Hvem+/+ or Hvem!/! GFP+HEL+ GC
B cells to the pre-transfer mix in Ptpn6f/f (SHP1)
Cd4Cre or control hosts. Data are pooled from four
experiments.
(D) Ratio of Hvem+/+ or Hvem!/! GFP+HEL+ GC
B cells to the pre-transfer mix in Ptpn11f/f (SHP2)
Cd4Cre or control hosts. Data are pooled from
three experiments.
(E) Representative flow-cytometric analysis of
CD40L surface mobilization on OT-II Tfh cells after
a 30 min of incubation; B cells were pulsed with a
titration of OVA peptide (0–10 mM).
(F) CD40L expression on OT-II Tfh cells stimulated
as in (E) (normalized to expression on unstimulated
Tfh cells). Data are pooled from three experiments.
(G) Representative flow-cytometric analysis of
CD40L surface mobilization on OT-II Tfh cells after
60 min of stimulation on OVA-peptide-pulsed
Hvem+/+ or Hvem!/! B cells.
(H) Normalized CD40L mean fluorescence in-
tensity on OT-II Tfh cells 30 or 60 min after stimu-
lation with OVA-loaded Hvem+/+ or Hvem!/!
B cells (2 or 10 mM). Data are pooled from two
experiments.
(I) Representative images of CD40 recruitment to
the immunological synapse with or without HVEM
and CD80 present in the lipid bilayer after 15 min of incubation with human Tfh cells; a standardized LUT is shown across panels so fluorescence can be directly
compared. Upper images show immunofluorescence (IF), middle images show overlayed IF and IRM, and lower images show IRM.
(J) Relative CD40 accumulation at synaptic interface in BTLA-transfected CD4+ T cell blasts and Tfh cells with or without HVEM and CD80 in the bilayer
(normalized to the condition without HVEM and CD80). Data are pooled from three independent donors and experiments.
Scale bars: 5 mm.Ordinary one-way ANOVAwith Bonferroni’s multiple-comparisons test (B–D), unpaired two-tailed Student’s test (F), paired two-tailed Student’s
test (H), or Mann-Whitney test (J): *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S5.
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pooled from 3 experiments. (G) Representative flow cytometric analysis of CD40L surface 
mobilization on OT-II Tfh cells after 60 min stimulation on OVA peptide-pulsed Hvem+/+ or 
Hvem-/- B cells. (H) Normalized CD40L MFI on OT-II Tfh cells 30 or 60 min after stimulation 
with OVA-loaded Hvem+/+ or Hvem-/- B cells (2 µM or 10 µM). Data pooled from 2 experiments. 
(I) Representative images of CD40 recruitment to the immunological synapse with or without 
HVEM and CD80 present in the lipid bilayer after 15 min incubation with human Tfh cells with 
standardized LUT across panels so fluorescence can be directly compared. Upper images show 
IF, middle images overlayed IF and IRM and lower images IRM. (J) Relative CD40 
accumulation at synaptic interface in BTLA-transfected CD4+ T cell blasts and Tfh cells with or 
without HVEM and CD80 in the bilayer, normalized to the no HVEM no CD80 condition. Data 
pooled from 3 independent donors and experiments. Scale bars are 5 µm. *P<0.05, **P<0.01, 
***<P0.001, ****P<0.0001. Ordinary One-Way Anova with Bonferroni’s multiple comparisons 
test B, C, D.  Unpaired two-tailed Student’s test panel, F. Paired two-tailed Student’s test H. 
Mann-Whitney J. See also Figure S5. 
 
 
HVEM-BTLA interaction reduces the amount of CD40-CD40L brought to synaptic 
interface 
For a Tfh cell to provide greater help to HVEM-deficient versus HVEM-expressing B 
cells in the same GC microenvironment during interactions that often last only for minutes, Tfh 
cell BTLA likely had to regulate mobilization of a preformed mediator. The best defined pre-
formed helper factor in Tfh cells is CD40L (Casamayor-Palleja et al., 1995; Koguchi et al., 2007; 
2012). However, it has been unclear whether the amount of preformed CD40L displayed on the 
T cell surface can be tuned by the strength of the TCR signal. As one approach to test this, OVA-
specific OT-II Tfh cells were incubated for 30 min with B cells that had been pulsed with a range 
of OVA-peptide concentrations. A 30 min incubation was chosen as a time that allowed cells to 
interact in the in vitro environment while being sufficiently short to ensure that only preformed 
CD40L could be mobilized. Although the B cells were not intentionally activated, they express 
ICOSL (Xu et al., 2013) and upregulated CD86 during the incubation (Fig. S5G), properties that 
may contribute to their ability to activate Tfh cells. Compared to unstimulated Tfh cell 
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expression of CD40L, B cells presenting increasing amounts of OVA-peptide led to an analog 
upregulation of CD40L on the Tfh cell surface by 30 min and this was further increased after 60 
min (Fig. 2.6E, F and Fig. S5H, I).  
We next tested whether HVEM-deficiency on the OVA-peptide pulsed B cell influenced 
CD40L upregulation on Tfh cells. Analysis at 30 and 60 min revealed a small but significant 
increase in CD40L exposure on Tfh cells interacting with HVEM-deficient B cells compared to 
Tfh cells interacting with WT B cells (Fig. 2.6G, H). Past studies have shown that CD40 is 
recruited to the immune synapse in a CD40L-dependent manner (Boisvert et al., 2004; Papa et 
al., 2017). We therefore returned to the supported lipid bilayer as another approach to test the 
ability of BTLA to regulate preformed CD40L upregulation. Human CD4+ T cell blasts and 
human Tfh cells were plated on the bilayer containing anti-CD3, ICAM1, CD40 and in some 
cases CD80. When HVEM was added to the bilayer, the amount of CD40 recruited to the 
synapse in the 15 min assay was reduced in both the blasts and the Tfh cells (Fig. 2.6I, J and Fig. 
S5J). These data suggest that BTLA can restrain the amount of preformed CD40L that is 
mobilized to the immunological synapse, and thus the quality of T cell help. 
To examine if increased T cell help could be read out in the Hvem-/- GC B cell as a 
transcriptional change, RNA-sequencing was performed on GC B cells from mixed BM 
chimeras. The top differentially expressed genes in Hvem-/- GC B cells compared to WT GC B 
cells corresponded to gene ontology biological processes for positive regulation of cell cycle 
progression (Fig. S5K). Previous studies have shown that Tfh cell help signals through CD40 to 
activate Myc and mTOR1 signaling in GC B cells that is required for clonal expansion (Calado 
et al., 2012; Dominguez-Sola et al., 2012; Ersching et al., 2017; Luo et al., 2018). GSEA analysis 
revealed that Hvem-/- GC B cells had increased Myc gene signatures compared to their WT 
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competitors (Fig. S5L) (Yu et al., 2005). Hvem-/- GC B cells were also enriched for a set of 
rapamycin-sensitive genes induced downstream of T cell help in GC B cells (Fig. S5M) 
(Ersching et al., 2017). These data are consistent with Hvem-/- B cells receiving increased T 
helper signals compared to their WT competitors. 
 
BTLA-deficiency in T cells leads to GC B cell expansion in the setting of Bcl-2-
overexpression 
HVEM mutations in human GC-derived lymphomas often occur in the setting of Bcl-2-
overexpression. To determine if the HVEM-deficient GC growth advantage occurred when B 
cells constitutively expressed Bcl-2, Hvem-/- BCL-2-tg mice were generated. Irradiated recipient 
mice were reconstituted with a mixture of CD45.2 Hvem-/- BCL-2-tg BM and congenically 
distinguished WT BCL-2-tg BM, and the chimeric animals were immunized with SRBC. The 
HVEM-deficient Bcl-2 GC B cells maintained their growth advantage compared to WT Bcl-2 
competitors (Fig. 2.7A). These data indicate that the growth promoting pathway mediated by 
HVEM-deficiency is distinct from the pro-survival pathway mediated by Bcl-2.  
Bcl-2 is very highly expressed in human FL and previous work has shown that lines of 
mice expressing higher amounts of Bcl-2 in B cells than the BCL-2-tg line have a higher 
propensity to form lymphomas (Ogilvy et al., 1999). To generate mice with higher expression of 
Bcl-2 in B cells, we transduced WT or Hvem-/- BM with a MSCV-Bcl-2-Thy1.1 construct. After 
reconstituting WT hosts, the Bcl-2 overexpressing BM chimeras generated large splenic GCs in 
unimmunized mice as early as week 6 after reconstitution and the GCs increased in size through 
14 weeks (Fig. 2.7B, C). Compared to WT chimeras, Hvem-/- chimeras had increased GC B cell 
expansion, suggesting that HVEM-deficiency cooperates with strong Bcl-2 overexpression.  
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Based on our findings in the preceding sections, we hypothesized that BTLA in the T cell 
could restrain the amount of help provided to the GC B cell in the setting of Bcl-2 
overexpression. To test this possibility, Btlaf/f Cd4Cre or control BM was transduced with the 
MSCV-Bcl-2-Thy1.1 construct and used to reconstitute Rag2-/- or Tcrb-/- mice. T cell-deficient 
mice were used as hosts to ensure an absence of radioresistant WT T cells. When Bcl-2-
overexpressing B cells developed in an environment where all the T cells were BTLA-deficient, 
there was increased GC B cell expansion in the spleen (Fig. 2.7D-F). VH- and VL- region PCR 
analysis of GC B cells from two of the Btlaf/f Cd4Cre BM chimeras with GC B cell frequencies 
exceeding 20% of splenic B cells showed evidence of clonal outgrowths (Fig. 2.7G). Clonal 
dominance was not observable for the light chain, perhaps because even small numbers of 
polyclonal cells prevent an abundant clone from dominating this PCR reaction. Taken together, 
these data indicate that BTLA on the T cell acts as a cell-extrinsic suppressor of Bcl-2-
overexpressing GC B cell expansion. 
 47 
  
Figure 2.7. BTLA-deficiency in T cells leads to GC B cell expansion in the setting of Bcl-2-
overexpression 
(A) Frequency of CD45.2 splenic Fo and GC B cells of Bcl-2 transgenic origin in mixed BM 
chimeras reconstituted with 30-50% Hvem+/+, Hvem+/-, or Hvem-/- Eµ-BCL-2-tg CD45.2 BM and 
50-70% WT Eµ-BCL-2-tg CD45.1/2 BM, 7d after immunization with SRBC. Data pooled from 
3 experiments. (B, C) The frequency (B) and number (C) of spontaneously forming splenic GC 
B cells in mice reconstituted for 6-14 weeks with Hvem+/+or Hvem-/- BM transduced with MSCV-
Bcl-2-Thy1.1. Data from 2 experiments. (D) Representative flow cytometric analysis of 
spontaneous GC formation in the spleen at 8 weeks of reconstitution with Btlaf/f or Btlaf/f Cd4Cre 
BM transduced with MSCV-Bcl-2-Thy1.1. Irradiated Rag2-/- or Tcrb-/- mice were used as hosts. 
(E, F) The frequency (E) and number (F) of spontaneously forming splenic GC B cells in BM 
chimeras from (D). Data pooled from 3 experiments. (G) VH- and VL- region PCR analysis of 
GC B cells from 2 Btlaf/f Cd4Cre chimeras with splenic GC outgrowths >20% and 2 Btlaf/f control 
chimeras. *P<0.05, **<P0.01, ****P<0.0001. Unpaired two-tailed Student’s test. 
 
Discussion 
The above findings establish that engagement of BTLA on helper T cells by HVEM on B 
cells signals to restrain B cell expansion during generation of GC cells and PBs, and also acts as 
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a restraint on B cells within the GC. The negative signaling into the T cell depends on the BTLA 
cytoplasmic domain and on SHP1 recruitment. HVEM engagement of BTLA reduces proximal 
TCR signaling and this reduces the output of CD40L and likely other preformed mediators from 
the T cell. HVEM thereby restrains B cell proliferation, differentiation and selection by reducing 
the delivery of helper signals from the T cell. We also find that the T helper signals restrained by 
the HVEM-BTLA interaction can exert their growth promoting effects on Bcl-2 overexpressing 
(pre-malignant) B cells, providing evidence that BTLA may act as a cell-extrinsic repressor of B 
cell lymphomagenesis. 
Under competitive conditions, proliferation of HVEM-deficient B cells was favored over 
WT B cells, in agreement with other models of B cell competition for T cell help (Gitlin et al., 
2014; Yeh et al., 2018). When C57BL/6 mice were deficient in HVEM in all B cells or BTLA in 
all T cells, while there was a trend for increased GC frequencies, there was not a significant 
enlargement of the GC response. A study in BALB/c mice reported an enlarged GC response 
when BTLA was absent, suggesting that the extent of BTLA-mediated regulation of GC B cells 
may be influenced by background genes (Kashiwakuma et al., 2010). Although we observed a 
slight increase in Hvem-/- GC B cell proliferation in mixed settings across several time points, we 
did not observe a progressive increase in Hvem-/- B cell representation within the GC over time, 
suggesting there should be increased output of Hvem-/- cells from the GC that accounts for the 
extra cells generated by proliferation. Our inability to detect increased GC B cell death or 
increased Bmem or PC compared to B cell representation in the GC may be because of a small 
effect size and the possibility that more than one of these output parameters is affected. As much 
as leading to increased proliferation of HVEM-deficient cells, lack of HVEM on some B cells 
appeared to reduce proliferation of competing WT B cells in the same animal. The exact 
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mechanism of the diminished response of the WT cells is unclear, but one possibility might be 
that Tfh cells harbor a limited amount of preformed helper factors (such as CD40L) and when 
greater amounts are delivered to some cells (Hvem-/- in this case) then less is available for the 
other cells present in the same microenvironment. A related possibility, suggested by the 
propensity of HVEM to convert stable synapses to motile kinapses, is that the increased stability 
of Hvem-/- B cell interactions with Tfh cells diminishes the contact of WT B cells with Tfh cells. 
B-T interactions generally occur over periods of minutes, making it unlikely that there is 
sufficient time for B cell-triggered induction of new transcription to impact the T cell help 
delivered during a given contact. Although previous work has shown that CD40L can be 
upregulated in a graded manner in proportion to the amount of TCR engagement, these studies 
were done over periods of 16-20 hrs and most likely involved transcriptional induction (Iezzi et 
al., 2009; Ruedl et al., 2000). In this study, we show that the rapid display of preformed CD40L 
protein on Tfh cells occurs in a manner proportional to the amount of MHC-peptide on the B 
cells. In accord with stronger signaling into the T cell mobilizing more preformed CD40L, 
previous work found that co-engagement of ICOS and the TCR enhanced CD40L externalization 
(Liu et al., 2014b; Papa et al., 2017). Based on these combined observations it can be suggested 
that the BTLA-mediated restraint of TCR-induced CD40L mobilization in T cells is due to the 
negative regulation of proximal TCR signaling.  
BTLA has been shown in biochemical studies to co-immunoprecipitate with SHP1 and 
SHP2 (Gavrieli et al., 2003; Watanabe et al., 2003). The molecular basis for the preferential 
coupling to SHP1 observed here in Tfh cells is not yet known and will need further investigation. 
These observations contrast with findings for PD-1, which preferentially associates with SHP2 in 
immune synapse studies with CD4+ and CD8+ T cells (Hui et al., 2017; Yokosuka et al., 2012) 
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and this study). However, an in vivo study has suggested that PD-1 function in effector CD8 T 
cells is not fully dependent on SHP2 (Rota et al., 2018). Given that PD-1 and BTLA are both 
highly expressed on Tfh cells, it will be important to determine whether PD-1 in Tfh cells in vivo 
depends on SHP2 since this may indicate qualitative differences in the type of regulation exerted 
in Tfh cells by these related checkpoint-family proteins.  
HVEM-mediated restraint of the B cell response did not begin immediately, suggesting 
that some temporal event needs to take place before HVEM-BTLA signaling becomes 
influential. We speculate that this may at least in part reflect the need for Bcl6 and BTLA 
upregulation in the activated T cell since the influence of HVEM-deficiency was lost in mice 
lacking Bcl6 in T cells. It is notable that HVEM surface levels are decreased on both mouse and 
human GC B cells compared to naïve and early activated B cells. Given the strong growth-
repressive effects observed in HVEM gain-of-function experiments, the reduced HVEM levels 
may be important in permitting transmission of the helper signals needed to support the strong 
proliferative responses of GC B cells.  
The impact of greater T cell help (indiscriminate of the amount of MHC-peptide 
presented) on the repertoire of B cells selected in the GC is not straightforward to predict. Our 
findings show that selection of NP-binding B cells is disfavored in HVEM-deficient B cells, 
perhaps indicating an increased competitiveness of carrier-specific B cells that would normally 
receive inadequate T cell help and be outcompeted by B cells responding to the readily 
accessible and highly multivalent NP hapten. Our inability to detect a differential effect of 
HVEM-deficiency on the proliferative response of Hy10 B cells responding to DEL (KA 107 
M−1) versus HEL (KA 1010 M−1) (Lavoie et al., 1992) may be because both antigens are in the 
high affinity range and the oligomeric state of the OVA conjugates may further diminish 
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differences in antigen capture and MHC-peptide presentation. In the context of NP-based 
immunizations, a similar increase in representation of non-NP binding B cells was seen in 
immunized PD-L1-deficient mice (Shi et al., 2018). Within the NP-binding Hvem-/- GC B cell 
population, there was a reduction in the fraction of cells harboring the affinity improving W33L 
mutation compared to the internal control WT cells. When compared to the WT control mixed 
chimeras, it was notable that there was an increase in the frequency of W33L mutations in the 
WT cells competing with Hvem-/- cells compared to those competing with other WT cells. One 
interpretation of these findings is that by diminishing the helper signals available to WT B cells, 
the HVEM-deficient B cells promote stronger selection for those WT B cells that are able to 
present the highest amounts of antigen. The combined observations suggest that negative 
costimulatory molecule signaling in Tfh cells is necessary to maintain the stringency of GC 
selection. A reduction in B cell selection stringency may explain the autoantibody production 
occurring in aged BTLA-deficient 129/SvEV mice (Oya et al., 2008) 
In agreement with a previous Bcl-2-overexpression BM chimera study (Boice et al., 
2016), where Hvem shRNA-targeted B cells preferentially contributed to GC-derived 
lymphomas, we found that B cell HVEM-deficiency cooperated with Bcl-2-overexpression in 
promoting GC outgrowth. The previous work also found that shRNA-targeting of Btla in 
hematopoietic cells (HSCs) led to GC outgrowth and this was attributed to a role for cis 
engagement of BTLA by HVEM leading to BTLA-mediated down-regulation of tumor-
promoting BCR signals (Boice et al., 2016; Huet et al., 2018; Verdière et al., 2018). In the 
experiments here, we did not observe any evidence for cis or trans effects of deleting BTLA 
from B cells, as measured by participation in the GC response. Instead, we found that deletion of 
BTLA from T cells led to a HVEM-expressing B cell growth advantage, including in 
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experiments with Bcl-2-overexpressing B cells. Although an important distinction between 
studies is that we measured GC participation and Boice et al., measured B cell 
lymphomagenesis, we believe that the different conclusions can be reconciled. Specifically, 
Boice et al., did not observe enrichment of BTLA-reduced B cells over control B cells in shRNA 
BM chimeras, making it unlikely that cis HVEM-BTLA interaction could be the principle 
mechanism of HVEM-mediated tumor suppression. While trans engagement by HVEM 
expressed in other B cells was also proposed (Boice et al., 2016), we believe the more likely 
explanation for the lymphomas arising in some of the mice reconstituted with BTLA knockdown 
HSCs is that a high knockdown efficiency was achieved in the Tfh cell compartment. Taking 
Boice et al., shRNA chimera data together with our findings, we believe that a revised model is 
supported in which HVEM mutation in B cells leads to a loss of negative signaling into Tfh cells, 
allowing HVEM mutant B cells to receive exaggerated helper signals that promote proliferation 
and accrual of AID-mediated mutations. In this regard, it is notable that FL has been highlighted 
for its rich presence of Tfh cells (de Jong and Fest, 2011; Huet et al., 2018; Verdière et al., 
2018). Importantly, the therapeutic benefit of elevating HVEM levels in the FL setting, as 
achieved by Boice et al., using CAR T cells (Boice et al., 2016), might act by diminishing Tfh 
cell function and thus support of FL cell growth. Future studies are needed to test if soluble 
HVEM can reduce Tfh cell function during GC responses and in lymphoma models where B cell 
HVEM has been mutated. 
 
  
 53 
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Figure S1. HVEM-deficiency increases GC B cell competitiveness in chronic GCs and GC output after 
an acute immune response. Related to Figure 1.
(A) Representative flow cytometric analysis of spleen Fo, GC, Bmem, and PC populations from mixed BM 
chimeras after SRBC immunization. (B) Contribution of CD45.2 cells to CD93+ immature BM B cells and 
splenic Fo B cells in mixed BM chimeras. Data pooled from 2 experiments. (C) Ratio of CD45.1/2 GC to 
CD45.1/2 Fo B cells in mixed chimeras made with ~70% of CD45.1/2 Hvem+/- or Hvem-/- BM with ~30% 
CD45.1 WT BM in Spleen (SPL), mesenteric LN (mLN) and Peyer’s Patches (PP), after intraperitoneal (i.p.) 
SRBC immunization. Data pooled from 2 independent experiments. (D) Frequency of GC B cells from mixed 
BM chimeras in dark zone (DZ) state (CXCR4highCD86low) after SRBC immunization. Data pooled from 3 
experiments. (E) Frequency of GC B cells in full Hvem+/- or Hvem-/- animals 6–8 days after SRBC immuniza-
tion. Data pooled from 3 experiments. (F) Frequency of GC B cells in Hvem+/+ and Hvem-/- mixed BM chimeras 
after SRBC immunization. Data pooled from 3 experiments. (G) Frequency of NP+ GC B cells in full, non-com-
petitive Hvem+/+ or Hvem-/-  chimeras. (H) Representative flow cytometric analysis for splenic NP+ GC B cell 
gating on day 6 NP-CGG alum response compared to unimmunized control. (I) Ratio of CD45.2 GC, memory 
B cells (Bmem), and plasma cells (PC) to CD45.2 Fo B cells at day 8 after SRBC immunization. Hvem-/- mixed 
chimera example shown in panel A. (J) Ratio of CD45.2 NP+ splenic Bmem (black circles) or PC (red trian-
gles) to CD45.2 NP+ GC B cells at day 7 and 21 after NP-CGG immunization. Data from 1 experiment and 
representative of 3 experiments. (K) Frequency IgG1+ of GC B cells in Hvem-/- mixed chimeras at day 8 after 
SRBC. (L) Frequency of anti-active Caspase-3+ GC B cells from NP-CGG alum immunized mixed BM chime-
ras day 6-7 directly ex vivo. Data pooled from 2 experiments. ‘Ctrl’ refers to the respective WT CD45.1 com-
petitor. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Unpaired two-tailed Student’s t test (B-G, I, K-L), Ordi-
nary One-Way Anova with Bonferroni’s multiple comparisons test (J).
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Figure S2. HVEM-deficiency provides B cells with a proliferation advantage early in the response and 
within the GC. Related to Figure 2.
(A) Representative flow cytometric analysis for gating GFP+ HEL+ B cells as HEL-intracellular-high CD138+ 
plasmablasts (PB) and HEL-intermediate IgDloFas+ GC B cells at days 4.5–5. (B) Frequency of HEL+ cells of 
total spleen in Bcl6f/f Cd4Cre or controls at day 5–7 after 2x-HEL-SRBC. Data pooled from 3 experiments. (C) 
Frequency of tdTomato+ of CD45.2 GC B cells after tamoxifen treatment. Data are pooled from 3 experiments. 
(D) Representative flow cytometric analysis of HVEM surface levels on Fo and GC B cells in CD45.2 compart-
ment. Red Hvemf/f S1pr2ERT2Cre, blue Hvem+/+ S1pr2ERT2Cre, and green Hvem-/-. (E) Representative flow cytomet-
ric analysis of HVEM surface levels in Hvemf/f Cγ1Cre Fo and GC B cells in red and Hvem+/+ Cγ1Cre in blue. (F) 
Hvemf/f Cγ1Cre and respective control CD45.2 mixed BM chimeras immunized with NP-CGG and analyzed day 
10–13 for the frequency of CD45.2 cells in the Fo and GC compartments. Data are pooled from 3 experi-
ments. *P<0.05, ***P<0.001, ****P<0.0001. Unpaired two-tailed Student’s t test (B, F).
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Figure S3. Conditional deletion of BTLA in T cells abrogates HVEM-deficient GC advantage. Related to 
Figure 4.
(A) BTLA MFI B220+ B cells (green), CD4+TCRβ+CXCR5+PD-1+ Tfh cells (red), and CD4+TCRβ+CXCR5-PD1- 
non-Tfh CD4+ T cells (blue) in Btlaf/f animals. Cre- left, Cd4Cre middle, and Mb1Cre right. (B) Contribution of 
CD45.2 Btlaf/f control or BTLA-B cell-deficient Btlaf/f Mb1Cre CD45.2 cells to Fo and GC populations in spleen of 
mixed BM chimeras made with ~50% CD45.2 and ~50% WT CD45.1 BM at day 7 after SRBC immunization. 
Data are pooled from 2 experiments. (C) Representative flow cytometric analysis of the frequency of Hvem-/- 
CD45.1/2 HEL+ GC B cells in Btlaf/f control (top) and Cd4Cre (bottom) recipients at day 6 after 2x-HEL-SRBC. 
(D) Frequency of Tfh cells of CD4+ T cells in Btlaf/f Cd4Cre animals in the spleen after SRBC. Data are pooled 
from 2 experiments. (E) Frequency of GC B cells of B cells in Btlaf/f Cd4Cre animals in the spleen after SRBC. 
Data are pooled from 2 experiments. (F) Frequency of HEL+ B cells of total splenocytes after Hy10 transfer 
and 2x-HEL-SRBC immunization. Data are pooled from 4 experiments. (G) BTLA MFI on OT-II T cells at 48 hr 
and 72 hr after HEL-OVA or DEL-OVA immunization. Data are pooled from 2 experiments. (H) BTLA MFI on 
Tfh cells at 3 days and 6 days after 2x-HEL-SRBC immunization. (I) Il21 mRNA transcript relative to Hprt from 
sorted splenic Tfh cells from Btlaf/f control CD45.2 or Cd4Cre mixed CD45.1/2 WT BM chimeras at day 7 SRBC 
immunization. Data are pooled from 2 experiments. ****P<0.0001. Unpaired two-tailed Student’s t test (B, 
D-I).
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Figure S4. BTLA-HVEM at the immunological synapse recruits SHP1 to inhibit signaling in Tfh cells. 
Related to Figure 5.
(A) Expression of BTLA on human tonsil Tfh cells, Treg cells and untransfected CD4+ blasts (Th). (B) Repre-
sentative images of synapse (s) or kinapse (k) states in BTLA-transfected human CD4+ T cell blasts on 
supported lipid bilayers containing anti-CD3 (UCHT1), ICAM1 and/or HVEM, CD80 as indicated. (C) Repre-
sentative images of SHP1 recruitment to the synapse in relation to PD-1 or mutant PD-1 Y248F. (D) Quantifi-
cation of SHP1 colocalization with WT PD-1 or mutant Y248F with or without (Ctrl) PDL-1 in the bilayer. (E) 
Representative images of SHP2 recruitment to the synapse in relation to PD-1 or mutant PD-1 Y248F. (F) 
Quantification of SHP2 colocalization with PD-1 or mutant Y248F with or without (Ctrl) PDL-1 in the bilayer. 
(G) Representative images of p-ZAP70 and (H) p-PKCθ in human CD4+ T cell blasts transfected with BTLA 
shown at the same LUT. Scale bars are 5 μm. *P<0.05, **P<0.01, ***<P0.001, ****P<0.0001. Mann-Whitney 
test (D, F.)
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MATERIALS AND METHODS 
 
Mice 
Adult C57BL6 CD45.1 mice at least 7 weeks of age were from the National Cancer Institute. 
Hvem flox animals (JAX stock 030862) and Hvem-deficient animals (Seo et al., 2018) were used 
in most studies. In one experiment mixed chimeras were generated from a separate Hvem-
deficient line (Wang et al., 2005). Btla flox animals have loxp sites flanking exons 4 and 5 of 
BTLA gene (J.-W.S., M.K. unpublished data). Full Btla deficient mice were from JAX stock 
006353 (Watanabe et al., 2003). Other lines included Ptpn6 flox (JAX stock 008336), Ptpn11 
flox (JAX stock 025758), Bcl6 flox (JAX 023727), Cγ1-Cre (JAX stock 010611), S1pr2-
ERT2Cre tdTomato Flox (Shinnakasu et al., 2016), Mb1-Cre (JAX stock 020505), Cd4-Cre 
(JAX stock 022071), Hy10 (Allen et al., 2007), OT-II (MGI 4836972), and Rag2-/- (JAX stock 
008449), Tcrb-/- (JAX stock 002118), Eµ-BCL-2-tg (JAX stock 002319), and Btla-y3/y3 
animals were generated and maintained in our laboratory. In most experiments, littermates were 
used as controls and experimental animals were co-caged in groups of 2-6 whenever possible. 
Male and female mice were used as both donors and recipients, except for OT-II animals, which 
required male donors. Animals were housed in specific pathogen free environment in the 
Laboratory Animal Research Center at UCSF and all experiments conformed to ethical 
principles and guidelines approved by the UCSF Institutional Animal Care and Use Committee. 
 
Generation of BTLAY3 mice 
Btla-y3/y3 animals were generated using crRNA1:TCATAAATTCCAGTTCCTGA targeting 
guide. The protocol followed Chen et al (Chen et al., 2016) with the main exception that the 
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standard square curve electroporation was performed twice with an interval of 3 seconds. RNP 
assembly followed standard protocol: 160 µM tracrRNA + 160 µM crRNA (Dharmacon), equal 
volume mix well 37°C, 30 min (80 µM sgRNA); 80 µM sgRNA + 40 µM Cas9 Protein equal 
volume, mix well 37°C 10 min (20 µM RNPs); leave on ice, each electroporation 10 µl of RNPs 
mix with 10 µl Opti-MEM with C57B6/J embryos. Standard electroporation: two pulses 30V for 
3 ms interval 100 ms. Embryos were transferred into pseudo-pregnant females.  
 
Bone marrow chimeras 
WT CD45.1, Rag2-/-, or Tcrb-/- where indicated were lethally irradiated with 1,100 rads 
gamma-irradiation (split dose separated by 3 h) and then i.v. injected with relevant BM cells. BM 
was harvested by flushing the tibia and femurs. For T cell depletion (when necessary), 250 µg of 
anti-CD4 GK1.5 (BioXcell) was injected I.V. at day -1 and day 0. 
 
Retroviral constructs and transductions 
Murine HVEM and Bcl-2 retroviral constructs were made by inserting the mouse open reading 
frame into the MSCV2.2 retroviral vector followed by an internal ribosome entry site (IRES) and 
Thy1.1 as an expression marker. Hvem point mutations were introduced by quick-change PCR 
and Hvem truncation was introduced by PCR. Retrovirus was generated by transfecting PLAT-E 
packaging cell line with 10 µg plasmid DNA and 10 µg Lipofectamine 2000 (Fischer). For 
transduction of BM, WT, Hvem-/-, or Btla-/- mice were injected I.V. with 3 mg 5-fluorouracil 
(Sigma). BM was collected after 4 d and cultured in DMEM containing 15% (vol/vol) FBS, 
antibiotics (penicillin (50 IU/ml) and streptomycin (50 µg/ml); Cellgro) and 10 mM HEPES, pH 
7.2 (Cellgro), supplemented with IL-3, IL-6 and stem cell factor (at concentrations of 20, 50 and 
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100 ng/ml, respectively; Peprotech). Cells were ‘spin-infected’ twice at days 1 and 2 and were 
transferred into irradiated recipients on day 3.  
 
Cell isolation, adoptive transfer 
Spleens were macerated and resulting cell suspensions were filtered through a 70 µm mesh into 
PBS supplemented with 2% FCS and 1mM EDTA. Cells were counted on a hemocytometer and 
frequency of HEL+ Hy10 B cell was determined by staining of HEL-AlexaFluor647 (made using 
Invitrogen Alexa Fluor 647 antibody labeling kit) positive B cells on the flow cytometer. Mixes 
of Hvem-/- or Hvem+/+ Hy10 and WT Hy10 congenically mismatched B cells were made at ratios 
of 1:4-1:1 as indicated in the figures. In some experiments OT-II T cells were co-transferred at a 
ratio of 1:5 Hy10 B cell as indicated in the figures. Mixtures of 5x104-2x105 cells were 
transferred i.v. in a volume of 200 µl into the retroorbital venous sinus. To visualize cell 
proliferation, cells were labeled with Cell Trace violet (Invitrogen). 
 
Immunizations 
Hosts were immunized with an intermediate affinity mutant 2x-HEL (Paus et al., 2006) (Gift of 
R. Brink) conjugated to SRBC (Colorado Serum Company) (Yi and Cyster, 2013) 
intraperitoneally (i.p.). If Hy10 B cells were co-transferred with OT-II, hosts were immunized 
with 50 µg of HEL-OVA or DEL-OVA (Yi and Cyster, 2013) mixed 1:1 with Sigma Adjuvant 
System (SAS, previously Sigma RIBI adjuvant) for a total volume of 200 µl. Animals were 
immunized with 100 µg NP-(20-29)-CGG (Biosearch technologies) mixed with 1:1 Alum 
(Alhydrogel) for a total of 200 µl volume. 2x108 SRBC (Colorado Serum Company) were 
injected in a volume of 300 µl. Tamoxifen (Sigma) was dissolved in Corn Oil (Sigma) at 20 
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mg/ml and injected at 2 mg/20g mouse i.p. TAM diet (Envigo) containing chow replaced normal 
chow when indicated.  
 
Flow cytometry 
Cells were stained on ice, in 96 round bottom plates in PBS supplements with 2% FBS and 1mM 
EDTA. The following antibodies were used: B220 APC-CY7 or BV785 (clone RA3-6B2), IgD 
FITC (clone 11-26c.2a), GL-7 Pacific Blue (clone GL7), FAS PE-CY7 (clone Jo2), CD38 
AlexaFluor647 (clone 90), CD45.1 PERCP-CY5.5, APC (clone A20), CD45.2 BV605, APC-
CY7 (clone 104), HVEM PE (clone LH1), BTLA AlexaFluor 647 (8F4), Ephrin-B1 Biotin 
(polyclonal, R&D), CXCR4 Biotin (clone 2B11/CXCR4), CD86 AlexaFluor647 (clone GL-1), 
IgG1 FITC (clone RMG1-1), CD138 BV421 (clone 281-2), CD73 PERCP-CY5.5 (clone 
TY/11.8), CD4 PE-CY7 (clone GK1.5), TCRβ Pacific Blue (clone H57-597), CXCR5 BV605 
(clone L138D7), PD-1 PE or FITC (clone 29F.1A12), CD40L PE (clone MR1), Vα2 PERCP-
CY5.5 (clone B20.1), Active caspase-3 (clone C92-605), Fixable viability dye eFluor780 
(eBioscience). NP-47-PE (Biosearch technologies). For intracellular staining, cells were fixed 
and permeabilized using BD Cytofix/Cytoperm kit. EdU detection was with Click-IT Plus EdU 
kit (Invitrogen). Data were collected on a BD LSRII and analyzed on FlowJo Software. 
 
qPCR and RNA-sequencing  
Hvem primers F: GGAGCTGGGATAGCTGGATTC R: TCTCCTGTTGTTCCTGGAAAGG, 
Il21 primers F: GCTCCACAAGATGTAAAGGG R: TTATTGTTTCCAGGGTTTGA. Cells 
were sorted using BD FACS ARAII. 104 cells or greater were sorted for qPCR and 5x104 cells 
were sorted for RNA-sequencing. RNA sequencing was prepared using Ovation RNA-seq 
 63 
System V2 from Nugen, KAPA Hyper prep labeling kit, NEXTflex DNA barcodes Adapter kit 
from Bioo Scientific. 100 bp paired end was run on HiSeq4000 at UCSF Institute for Human 
Genetics. Data was run through STAR alignment and Deseq2. 
 
GSEA and Gene Ontology 
GSEA analysis (v3.0) through the BROAD was performed using standard settings: 1000 number 
of permutations, collapsed data to gene symbols, permutation type phenotype, enrichment 
statistic weighted. Data for Rapamycin sensitive DEC205-WT GC B cell genes was accessed 
(Ersching et al., 2017) and significant genes, defined as padj <0.01 with >2 fold increased in 
untreated v. Rapa treated, were made into a manually curated gene list. Yu Myc targets UP was a 
premade GSEA gene list. Gene ontology was performed using Enrichr platform (Kuleshov et al., 
2016). 
 
NP VH186.2 mutation analysis 
For bulk GC sequencing- PCR reaction 1. PCR1 For primer: 
CATGGGATGGAGCTGTATCATGC Rev primer: CTCACAAGAGTCCGATAGACCCTG 
PCR2 (nested) For primer: GGTGACAATGACATCCACTTTGC Rev primer: 
GACTGTGAGAGTGGTGCCTTG and the blunt end cloned into TOPO vector. Plates were sent 
to TacGen for plasmid prep and Sanger sequencing (Bannard et al., 2016). For single cell 
sequencing- NP+ cells were sorted into lysis buffer and frozen in 96U bottom plates. Nested PCR 
with primers and sent for sequencing. 186-EF: GTATCATGCTCTTCTTGGCAGC 186-IF: 
ACAGTAGCAGGCTTGAGGTCTG 186-IR: CCCAATGACCCTTTCTGACTC 186-ER: 
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TGAGGATGTCTGTCTGCGTCA (Yang et al., 2012). Data was analyzed using IgBLAST and 
the frequency of W33L were counted in non-frame shifted IGHV1-72*01 sequences. 
 
Tfh cell CD40L surface mobilization  
Tfh cells were generated by transferring OT-II into WT mice on day -1 and immunizing retro-
orbitally with 2 x 108 SRBCs (Colorado Serum Company) conjugated to 10 µg (0.85 mg/mL) 
HEL-OVA and mixed with 150 µg (1mg/mL) poly I:C (GE Healthcare) pre-heated for 10 min at 
60ºC in a total volume of 350 µL on day 0. On day 3, spleens were harvested and CD4+ T cells 
were isolated through negative selection by depletion with anti-CD8a biotin, anti-CD11c biotin, 
and anti-CD19 biotin antibodies and EasySep Mouse Streptavidin RapidSpheres (Stemcell) in 
complete RPMI. For B cells, spleens were harvested from WT or Hvem-/- mice. Splenocytes were 
CTV labeled at 0.5 µM and pulsed with 10 µM, 2 µM, 0.4 µM, or 0.08 µM OVA 323-339 
peptide (GenScript) antigen or no antigen for 2 h at 37°C. The splenocytes were all washed three 
times and 8 x 105 splenocytes were combined with 4 x 105 CD4+ T cells in a 96-well round 
bottom plate. To facilitate detection of surface exposed CD40L the cells were incubated in the 
presence of 1 µg/ml anti-CD40L PE antibody as previously described (Gardell and Parker, 2016; 
Koguchi et al., 2007). After 30 or 60 min incubation at 37°C, T cells were harvested, stained, and 
analyzed on the LSRII flow cytometer. Anti-CD11c biotin antibody and EasySep Mouse 
Streptavidin RapidSpheres (Stemcell) were used to deplete dendritic cells in two experiments 
with no differing results. 
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Assessment of BCR clonality by PCR 
Assessment of clonality by PCR of J558 heavy chain, and κ light chains from genomic DNA 
from 2x104 FACS sorted GC B cells from 8 week old Btlaf/f Cd4Cre and Btlaf/f control chimeras 
(Cobaleda et al., 2007; Muppidi et al., 2014).  Primers:  
VHJ558 CGAGCTCTCCARCACAGCCTWCATGCARCTCARC,  
JH4 CGAGCTCTCCARCACAGCCTWCATGCARCTCARC,  
Vκ GGCTGCAGSTTCAGTGGCAGTGGRTCWGGRAC,  
Jκ5 GGCTGCAGSTTCAGTGGCAGTGGRTCWGGRAC. 
 
Human CD4+ T cell isolation, stimulation, and transfection 
Primary human CD4+ T cells were isolated using the RosetteSep Human CD4+ T Cell 
Enrichment Cocktail (StemCell Technologies) as per the manufacturer’s instructions from 
leukocyte cones provided by UK National Health Service Blood and Transplant. Isolated cells 
were cultured in RPMI-1640 supplemented with 10% FCS, 4 mM L-glutamine, 10 mM HEPES, 
1% non-essential amino acid solution (Gibco), and 1% penicillin-streptomycin solution (Gibco) 
at 37°C, 5% CO2 for between 24 and 72 h before stimulating. Cells were diluted to 1x106/ml in 
supplemented RPMI-1640 containing 50 U/ml recombinant IL-2 (PeproTech) and anti-human 
CD3/CD28 Dynabeads (Gibco) at 1x106/ml. Cells were cultured for 3 days before the beads 
were removed by magnetic separation and the medium replaced with fresh supplemented RPMI-
1640 + 50 U/ml IL-2. Cells were cultured for a further 4 days with medium replaced and cells 
diluted to 1x106/ml as required.  
 
Human BTLA was cloned into pGEM-SnapTag vector. This vector was used to produce mRNA 
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in vitro using the mMESSAGE mMACHINE T7 Transcription Kit (Thermo Fisher Scientific) as 
per the manufacturer’s instructions. Transfection was performed 24 h before imaging. Cells were 
washed 3 times with OptiMEM (Gibco) at room temperature and resuspended at 2.5x106 
cells/100 µl. 2.5 – 7.5 µg mRNA encoding WT or mutant BTLA-SNAP-tag was added to 
2.5x106 cells, which were gently mixed, transferred to a Gene Pulser cuvette (BioRad) and 
pulsed for 2 ms at 300 V in an ECM 830 Square Wave Electroporation System (BTX). Cells 
were then immediately transferred to supplemented RPMI-1640 at 1x106/ml and cultured for 24 
h. The amount of mRNA used was optimized for each T cell donor and mRNA preparation by 
performing multiple transfections with titrated mRNA amounts, then assessing total BTLA 
expression after 24 h by staining with AlexaFluor 647-conjugated anti-BTLA (BioLegend, 
344520) and comparing to Quantum AlexaFluor 647 MESF calibration beads (Bangs 
Laboratories) by flow cytometry. Conditions giving ~10,000 transfected BTLA/cell were 
selected for imaging. 
 
Human Tfh cell isolation 
Human Tfh cells were isolated from tonsils provided by UK National Health Service Blood and 
Transplant. Tissue was kept on ice prior to use and processed within 3 h of surgery. Tonsils were 
washed in ice-cold Hank’s balanced salt solution (HBSS; Gibco) supplemented with 2% FCS, 
5% penicillin-streptomycin solution (Gibco), and 500 µg/ml normocin (Invivogen). Whole 
tonsils were partially submerged in cold, supplemented HBSS and dissected into pieces 1-5mm 
in size using a sterile scalpel. Tissue fragments were separated into multiple 70 µm cell strainers 
and crushed using a 20 ml syringe plunger, then washed with cold, supplemented HBSS. 
Strained samples were pooled and passed through a 40 µm cell strainer then pelleted at 400 g for 
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10 min and resuspended in 15 ml cold, supplemented HBSS. Peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll-Paque density gradient centrifugation. Total CD4+ T cells were 
isolated from the PBMC fraction using the EasySep CD4+ isolation kit (StemCell Technologies) 
and kept on ice in supplemented HBSS. Cells were immediately stained with anti-CXCR5 
conjugated to either AlexaFluor 488 (BD Biosciences, 558112) or PE/Cy7 (BioLegend, 356923) 
depending on the downstream application, washed, and the CXCR5high population sorted using a 
FACSAria III cell sorter (BD Biosciences). Isolated Tfh cells were resuspended at 5x106/ml in 
supplemented RPMI-1640 and cultured for 3 h at 37°C, 5% CO2 before being used for imaging. 
A small number of cells were retained and stained with anti-CXCR5 and anti-PD1 conjugated to 
AlexaFluor 488 (BioLegend, 329935) or AlexaFluor 647 (BioLegend, 329910), washed, and 
analysed by flow cytometry to confirm the purity of the CXCR5high PD1+ population. 
Quantification of BTLA and HVEM surface expression 
Isolated whole CD4+ populations or isolated Tfh cells were stained with with AlexaFluor 647-
conjugated anti-BTLA (BioLegend, 344520) and compared to Quantum AlexaFluor 647 MESF 
calibration beads (Bangs Laboratories) by flow cytometry. HVEM levels on B cells were 
determined by staining PBMCs from whole blood with anti-CD19-PE-Cy7 (BD Biosciences; 
560911), anti-CD38-AlexaFluor 488 (BioLegend; 303511), anti-CD27-BrilliantViolet421 
(BioLegend; 356417), anti-CD20-PE (BioLegend; 302305), and anti-HVEM-AlexaFluor 647 
(BD Biosciences; 564411). B cell subsets were gated as follows: Activated (CD19+ CD20+ 
CD27+ CD38+), Memory (CD19+ CD20+ CD27+ CD38-), immature/transitional (CD19+ 
CD20+ CD27- CD38+), and plasmablasts (CD19+ CD20- CD27+ CD38+). HVEM intensity on 
each cell subset was converted to absolute protein numbers by reference to Quantum AlexaFluor 
647 MESF calibration beads (Bangs Laboratories). Based on the mean HVEM expression on 
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activated B cells of ~35,000/cell, minimum surface density was estimated at ~35 molecules/µm2 
assuming an upper limit of ~1000 µm2 total area. 
 
Supported lipid bilayer preparation and use 
Supported lipid bilayers (SLB) were prepared as described previously (Choudhuri et al., 2014). 
Briefly, micelles of 1,2-dioleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids Inc.) 
supplemented with 12.5% 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl) 
iminodiacetic acid) succinyl]-Ni (Avanti Polar Lipids Inc.) were flowed onto glass coverslips 
hydroxylated with piranha solution, plasma cleaned, and affixed with adhesive 6-lane chambers 
(Ibidi). SLBs were blocked and washed, then incubated with recombinant His-tagged proteins of 
interest (produced in-house with the exception of HVEM-Fc-His, which was a gift from Prof. 
Simon Davis, University of Oxford) at the requisite concentrations to achieve the desired 
density: 30 molecules/µm2 for UCHT1-FaB, 200 molecules/µm2 for ICAM1, 100 molecules/µm2 
for CD80, 35 molecules/µm2 for HVEM-Fc-His, and 100 molecules/µm2 for CD40. The specific 
combination of unconjugated proteins or proteins conjugated to different dyes (AlexaFluors 405, 
488, 568, and 657) was varied to suit the demands of each experiment. Within 2 h of preparation, 
SLBs were pre-warmed to 37°C and cells were infused into the SLB chambers at ~5x105/lane for 
CD4+ cells or ~1x105/lane for Tfh cells. Samples were either incubated for 3 or 15 min at 37°C 
then fixed with warm 4% para-formaldehyde in PHEM buffer (60 mM PIPES, 25 mM HEPES, 
10 mM EGTA, 2 mM MgCl2, pH 6.9) for 10 min, or imaged live. In experiments involving 
labelling of transfected BTLA-SNAP-tag, cells were incubated with 0.5 µM SNAP-Cell 647-SiR 
ligand (New England BioLabs) in supplemented RPMI-1640 for 30 min at 37°C, washed 3 
times, and incubated for a further 30 min prior to addition to SLBs. 
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Immunofluorescence staining 
Fixed cell samples were exposed to a second round of fixation in PHEM buffer with 2% PFA 
and 3% BSA (bovine serum albumin) for 10 min at room temperature in order to reduce non-
specific adsorption of probing antibodies to the coverslip. Samples were washed 3 times with 
PHEM buffer, permeabilised with 0.1% saponin in PHEM buffer for 15 min, then washed 3 
more times with PHEM buffer. Samples were then quenched with 100mM glycine for 20 min 
and blocked with 6% BSA in PHEM buffer for 1 h before washing 3 times with PHEM buffer. 
Samples were then incubated with the appropriate primary rabbit antibody (anti-SHP1, Santa 
Cruz Biotechnology, sc-287; anti-SHP2, Santa Cruz Biotechnology, sc-280; anti-pY493 ZAP70, 
Cell Signaling Technology, 2704; anti-pT538 PKCθ, Cell Signaling Technology, 9377) in 
PHEM buffer with 0.02% saponin, 3% BSA for 1 h. Washing was performed 3 times with 
PHEM buffer, 0.1% saponin, 3% BSA with 2 min between each wash, before incubating with 
goat anti-rabbit F(ab')2 conjugated to AlexaFluor 568 (ThermoFisher Scientific, A-21069) in 
PHEM buffer with 0.02% saponin, 3% BSA for 45 min. Samples were finally washed 5 times 
with PHEM buffer, 0.1% saponin, 3% BSA with 2 min between each wash before imaging. A 
sample stained using only secondary antibody was included in each experiment as a background 
control. 
TIRF and confocal imaging 
TIRF imaging was performed on an Olympus cellTIRF-4Line system using a 150x (NA 1.45) oil 
objective. Imaging of live samples was performed at 37°C, and of fixed samples at room 
temperature. Confocal imaging was performed on a 37°C-controlled Olympus FV1200 confocal 
microscope using a 20x (NA 0.75) air objective. 
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Image analysis 
All image analysis was performed using the ImageJ software. Thresholded IRM images were 
used to define the contact area of each cell, and all pixels therein used to calculate the mean 
fluorescence intensity (MFI) for a given channel. Pearson colocalization coefficients (PCCs) 
were also calculated only for IRM-defined contact areas using the Coloc 2 plugin to perform 
pixel intensity correlation between channels. Identification and tracking of cells for comparison 
of adhesion and movement was performed using the TrackMate plugin, with total cells detected 
from bright field images and those forming contacts identified through IRM images. Cells were 
qualitatively assigned as forming synapses or kinapses based on the relative centrality and 
symmetry of the predominant UCHT1 and ICAM1 signals. Synapses were defined as having 
approximately central UCHT1 accumulations completely surrounded by a ring of 
ICAM1; kinapses as having a highly polarized UCHT1 accumulation with ICAM1 adjacent but 
not surrounding. Cells not fitting either category were defined as unassigned. 
 
In-situ analysis of interaction of SHP1 and SHP2 with PD-1 
Supported lipid bilayers presenting relevant ligands were prepared as described above. Biotin-
CAP-phosphatidylethanolamine was used at a 0.04 molar percentage to that of 
dioleoylphosphatidylcholine (DOPC). Monobiotinylated Okt3 (anti-CD3 antibody, from 
Ebiosciences) was used at 0.5 µg/ml. The following ligands were presented on the bilayer by 
means of coordination chemistry between DOGS-NTA and poly-Histidine tag: 12x-His ICAM1 
ectodomain at ~200 molecules/µm2; 12x-His CD58 ectodomain at ~300 molecules/µm2; and 
12x-His PDL1 ectodomain at ~300 molecules/µm2. Freshly isolated human CD8 T cells were 
electroporated with mRNA encoding PD-1 GFP or PD-1 Y248F GFP and cultured for ~8 h 
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(Zhao et al., 2005). Cells were introduced into the flow-cells containing lipid bilayers at 37 °C 
and fixed after 10 min by flowing in pre-warmed 2% EM-grade formic acid in PBS. SHP1/2 
staining was performed as described above. Images were acquired on a Nikon Eclipse Ti 
inverted fluorescence microscope using an Apo TIRF 100x 1.49 NA oil objective. Diode lasers 
(488 nm, 561 nm and 641 nm, from Coherent) were used for TIRF illumination at the plane of 
bilayer. An AOTF (from Solamere Technologies) was used for choosing appropriate excitation 
wavelengths. A xenon arc lamp (from Newport) filtered at 490nm was used for reflection 
imaging of cell contacts with the bilayer. Nikon perfect focus systemÒ was used to achieve 
consistent illumination and also to compensate for axial chromatic aberration. NIS-Elements 
software (from Nikon) was used for hardware control of the microscope, filter and shutter 
wheels, AOTF, and the EMCCD camera  (Andor DU-897 X-4654) during image acquisition. 
EMCCD camera was operated in the normal gain mode and well under saturation. Custom 
written macros were used for automated image analysis in ImageJ 1.44o (from NIH). Cell-
boundaries were defined based on segmented ('Default' algorithm in ImageJ) reflection images. 
Back-ground subtracted images were used for calculating average fluorescence intensity from 
each cell. Pearson Cross-correlation Coefficient (PCC) values between thresholded green and 
far-red channels ('MaxEntropy' algorithm in ImageJ) were calculated for each cell to 
quantitatively measure the extent of colocalization. Cluster statistics were computed using the 
'Analyze Particles' routine in ImageJ after thresholding the images using the 'MaxEntropy' 
algorithm. Statistical significance was assessed by Mann-Whitney test using the GraphPad 
Prism5 software.  
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Quantification and statistical analysis 
All statistical tests were done with GraphPad Prism software. The appropriate statistical test for 
each experiment is noted in the figures. 
 
Data availability 
Raw and processed data files for RNA sequencing analysis have been deposited in the NCBI 
Gene Expression Omnibus under accession number GSE130095. 
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CHAPTER 3: CONCLUSION 
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Figure 3.1. Model 
(Top) HVEM-expressing GC B cell recruits BTLA to immunological synapse. BTLA signals 
into Tfh cell through SHP1, which inhibits the strength of TCR signal and amount of preformed 
CD40L mobilized to the cell surface. In the absence of HVEM, BTLA is not recruited to the 
immune synapse and the amount of preformed CD40L mobilized to the surface is increased. The 
HVEM-deficient B cell receives increased CD40 signaling. (Middle) When a high affinity B cell 
presents antigen to a Tfh cell, it receives stronger helper signals compared to a low affinity B 
cell. However, when a HVEM-deficient low affinity B cell presents antigens it receives helper 
signals more similar to a high affinity B cell. (Bottom) Bcl-2 overexpressing B cells encounter 
antigen and enter the GC. Over time and accumulating AID-induced mutations, HVEM is 
mutated and the HVEM-deficient Bcl-2-high GC B cells receive more T cell helper cues that in 
combination with their enhanced survival lead to lymphomagenesis.  
 
In this study, we aimed to show how HVEM regulates the GC B cell response in mice 
(Fig. 3.1). We found that HVEM is an intrinsic negative regulator of GC B cell responses. 
HVEM engages BTLA in trans on the T cell. BTLA recruits SHP1 which negatively regulates T 
cell signaling and the amount of preformed CD40L mobilized to the surface of the Tfh cell. 
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Thus, the HVEM-deficient GC B cell receives stronger CD40 signals when BTLA is not 
recruited to the immune interface.  
While Tnfrsf14 transcripts are expressed at similar levels in naïve and GC B cells in 
mouse, HVEM surface protein is reduced on GC B cells (Mintz et al., 2019). A similar pattern of 
HVEM mRNA and protein expression is evident in human follicular and GC B cells (Duhen et 
al., 2004)(unpublished observations). A study of FL has confirmed the specificity of this low-
level staining by identifying some cases that are surface positive and others (most likely HVEM 
mutant) that are surface negative (Kotsiou et al., 2016). The apparent post-transcriptional 
downregulation of HVEM in GC B cells suggests these cells need to have tight control of HVEM 
protein abundance. However, what regulates HVEM protein expression in GC B cells remains 
unknown and is an area that merits future investigation. 
Using a mixed chimeric mouse system, HVEM-deficiency was found to provide B cells 
with a competitive advantage in the GC compared to the follicular compartment (Mintz et al., 
2019). HVEM haploinsufficiency provided GC B cells with an intermediate advantage, 
suggesting that the amount of HVEM expressed on the B cell regulates competitiveness. HVEM-
deficient B cells showed a competitive advantage at both the pre-GC and GC stages (Mintz et al., 
2019). HVEM-deficiency led to a small increase in the frequency of pre-GC and GC B cells 
entering into the cell cycle, providing at least a partial explanation for their increased 
representation. Following immunization with an NP-haptenated protein, HVEM-deficient GC B 
cells showed preferential expansion of the non-NP binding relative to the NP-binding B cells. 
Since the NP-binding cells tend to rapidly achieve high affinity, these data suggested HVEM-
deficient B cells with lower affinity were being preferentially selected. In additional support for 
this model, HVEM-deficient NP-specific GC B cells had reduced high affinity W33L mutations 
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compared to HVEM-expressing competitors in the same mice. Comparison with W33L mutation 
frequencies in control chimeras suggested that the most prominent effect was an increased 
stringency of selection for W33L mutations in wild-type cells that were in competition with 
HVEM-deficient cells. One model to explain these observations is that the wild-type GC B cells 
needed to acquire more antigen through a higher affinity BCR in order to receive competitive T 
helper cell positive selection signals. These data are similar to what was observed in chimeric 
PD-L1-deficient GCs, where PD-L1-deficient GC B cells were preferentially expanded amongst 
the non-NP binding cells and had reduced high affinity mutations (Shi et al., 2018). While the 
data together suggest that negative regulators maintain the stringency of Tfh cell selection of GC 
B cells, the PD-L1 study did not observe an increase in high affinity mutations in the PD-L1-
expressing GC B cells competing with the PD-L1 deficient GC B cells, suggesting that these 
regulatory molecules do not act in an identical manner.  
Using gain and loss of function approaches, we demonstrated that the growth restraining 
actions of HVEM in GC B cells depended on BTLA expression by T cells (Mintz et al., 2019). 
Although BTLA is highly expressed in B cells and HVEM–BTLA have been shown to engage in 
cis interactions in HEK-293t cells (Cheung et al., 2009a; Watanabe et al., 2003), BTLA-deficient 
B cells were not over-represented in GCs, suggesting BTLA is not acting in cis to regulate B cell 
responses (Mintz et al., 2019). HVEM-BTLA cis-interactions were presented to explain Boice et 
al.’s finding that sh-RNA targeting of Btla phenocopied the increased GC lymphomagenesis seen 
in Tnfrsf14-targeted Vav-Bcl-2 BM chimeras (Boice et al., 2016; Huet et al., 2018; Verdière et 
al., 2018). The authors, however, did not report a preferential enrichment of BTLA-knock-down 
cells in the B cell compartment as they did for HVEM-knockdown cells. We reconcile the 
findings by noting that the global hematopoietic shRNA knockdown approach would be 
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expected to reduce BTLA in Tfh cells as well as in B cells. In accord with the model that BTLA 
acts in trans, no mutations have been reported in the coding region of BTLA in B cell 
lymphomas. It has been suggested that BTLA expression is lost in a significant fraction of FLs 
through epigenetic regulation of KMT2D methylation (Boice et al., 2016), and an additional 
report observed a diversity of BTLA expression in FL samples (Carreras et al., 2019). Further 
work will be needed to understand if heterogeneity of human BTLA expression in the GC and 
follicular B cell compartments is relevant to lymphomagenesis.  
Early evidence that HVEM mutations may be enhancing the ability of FL cells to present 
antigen to T cells came from the observation that FL patients with BM transplantation had 
increased rates of graft versus host disease (Kotsiou et al., 2016). Using FL cells as antigen 
presenting cells in allogeneic mixed lymphocyte reactions, they found HVEM-mutated FL cells 
induced more division in both CD4+ and CD8+ T cells than HVEM-expressing FL cells. When 
HVEM-expressing FL cells were incubated with a BTLA antagonist both allogeneic CD4+ and 
CD8+ T cell proliferation increased, while the antagonist had no effect on the response elicited 
by HVEM-mutated FL cells. These findings suggest that HVEM on FL cells inhibits signaling in 
allogeneic T cells through engagement of BTLA (Kotsiou et al., 2016).  
Planar lipid bilayer imaging of human T cells showed co-localization of SHP1 with 
BTLA that was largely reversed when BTLA’s ITIM/ITSM motif was mutated; BTLA did not 
colocalize with SHP2 (Mintz et al., 2019). These results have been supported by two 
independent studies finding BTLA preferentially recruits SHP1 in mouse CD4+ T cells (Celis-
Gutierrez et al., 2019). In addition to its ability to directly dephosphorylate CD3-zeta, BTLA 
inhibited phosphorylation of ZAP-70 and PKC-theta in human Tfh cells. Analysis of mice 
homozygous for a cytoplasmic domain mutant of BTLA that lacks all three tyrosines including 
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its SHP1 recruiting ITIM/ITSM motif, confirmed that BTLA reverse signaling was required for 
HVEM function in B cells. These data suggest that HVEM-expressing cells are selected through 
trans signaling into BTLA expressing Tfh cells during cell-cell contacts. Experiments in mice 
lacking SHP1 or SHP2 in T cells further supported the conclusion that BTLA signaling via SHP1 
into the Tfh cell modulates the amount of help provided to HVEM-expressing B cells (Mintz et 
al., 2019). 
While early T cell-B cell interactions can last for an hour, in the GC the majority of 
interactions take place on the range of minutes. Based on finding that HVEM-deficiency led to 
an intrinsic growth advantage in B cells, it was inferred that HVEM-deficient B cells must 
receive greater help than their wild-type counterparts during these brief interactions. CD40L is 
the main helper factor known to be preformed in Tfh cells. When Tfh cells were exposed in vitro 
to B cells presenting increasing amounts of MHC-peptide complexes, an analog upregulation of 
CD40L was observed (Mintz et al., 2019), indicating that the extent of mobilization of preformed 
CD40L to the Tfh cell surface is tuned to the TCR signal strength. In accord with this notion, 
HVEM-deficient B cells induced greater CD40L surface mobilization in Tfh cells when 
compared to HVEM-expressing B cells displaying the same amount of MHC-peptide. 
Furthermore, CD40 recruitment to the immune synapse was decreased when HVEM was 
included in lipid bilayers, suggesting that CD40L mobilization to the synapse is reduced by 
HVEM-BTLA interactions. While these data do not rule out additional factors that HVEM-
BTLA may be regulating, such as cytokines, they suggest that BTLA inhibits Tfh cell help by 
restraining the amount of CD40 signals delivered to GC B cells. In further support of this model, 
HVEM-deficient GC B cells competing with wild-type GC B cells exhibited an increased Myc 
gene signature (Mintz et al., 2019). 
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In planar lipid bilayer studies, the presence of HVEM in the bilayer transformed the 
stable, centered immune synapse into a motile, polarized kinapse structure (Mintz et al., 2019). 
These results suggested that BTLA inhibits strong contacts with HVEM-expressing cells. 
Surprisingly, 2-photon microscopy-based imaging of Tfh cells interacting with HVEM-deficient 
and wild-type GC B cells in intact lymph nodes did not reveal differences in the time of contact 
or surface area of interactions (unpublished observations). Further work is needed to determine if 
there are differences in interaction stability early versus late in the GC response. 
In models of Bcl-2-overexpression, HVEM-deficiency continued to provide GC B cells 
with an advantage and it led to accelerated lymphomagenesis, suggesting that HVEM deficiency 
was acting in a separate pathway from Bcl-2 (Boice et al., 2016). Overexpression of Bcl-2 in 
mice lacking BTLA in T cells led to similar pre-malignant outgrowths as occurred in HVEM-
deficient Bcl-2 over-expressing Bcl-2 mice. These data provide some of the first evidence of a 
cell-extrinsic tumor suppressor distinct from the mechanism of CD8+ and NK cell immune 
surveillance.  The ways in which increased signaling via CD40 and other T cell-derived helper 
factors cooperates with Bcl-2-overexpression in lymphoma development remains to be fully 
elucidated. 
Given HVEM’s complex signaling biology and the expression of several of HVEM’s 
ligands on cells in immune microenvironments, it remains to be determined if loss of HVEM in 
GC-derived lymphomas alters parameters in addition to the BTLA-HVEM axis. While a third of 
TNFRSF14 mutations are truncating, the remaining two-thirds may still preserve HVEM protein 
expression but alter its ability to engage ligands. For instance, HVEM-Y61A, a mutation that 
disrupts binding to BTLA and CD160, is found in FL patients. In particular, it will be interesting 
to learn if loss of HVEM or particular mutations alter FL cell interactions with CD160 
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expressing cytotoxic CD8+ T cells or NK cells and immune surveillance in the tumor 
microenvironment. It will also be interesting to learn if LIGHT engages with HVEM on B cells 
to determine GC B cell outcomes, and if HVEM can signal into the B cell. Lastly, given BTLA’s 
high expression on B cells it will be important to better understand if the ability of this molecule 
to negatively regulate BCR signaling is relevant to lymphomagenesis or other B cell-mediated 
diseases. 
The HVEM—BTLA axis may be a regulatory pathway suppressing Tfh cell lymphomas. 
Interestingly, high expression of BTLA correlated with a positive clinical outcomes in AITL 
through RNA sequencing of the entire tumor (Iqbal et al., 2010). We hypothesize that the high 
levels of BTLA mRNA could be maintained on the Tfh cells to inhibit TCR signaling strength 
when interacting with HVEM-expressing B cells, thereby limiting tumor growth. In accord with 
this logic, a TNFRSF14 mutation has been found in one AITL sample in which the entire tumor 
was sequenced (Cannons et al., 2010). These data raise the possibility that loss of HVEM in B 
cells in the tumor environment could be driving Tfh cell outgrowth. Interestingly, AITL cells 
continue to express high levels of PD-1 (Odejide et al., 2014).  
Therapeutic approaches  
The work in this dissertation adds to other studies discussed in the introduction in 
pointing to possible novel therapies to stop lymphoma progression. Blunt approaches can be 
considered if a patient it at high risk of developing GC-derived lymphomas or failed prior 
therapies. These include depleting Tfh cells through anti-CD4 antibodies and blocking CD40-
CD40L, ICOS-ICOSL and IL4-IL4R signaling axes. More modest approaches could be to 
augment SLAMF receptor function in T cells. Restoring negative regulation of GC B cell 
responses by enhancing PD-1-PD-L1 and BTLA-HVEM axes could inhibit GC B cell outgrowth. 
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This has been demonstrated in a mouse model of FL where anti-CD19 CAR-T cells delivered 
soluble HVEM to the tumor microenvironment and likely inhibited Tfh cell help to FL B cells by 
engaging BTLA. Augmenting FasL-Fas interaction in lymphomas that retain this pathway could 
have therapeutic benefit. Better definition of the dependency of some GC lymphomas on T cells, 
and of tumor suppressors that are acting in trans, may identify more opportunities for restoring 
those tumor suppressors using CAR T cell-type approaches or other surface receptor-targeted 
therapeutic strategies. It is also possible that targeting the cues that organize GCs and foster 
interactions between GC B cells and Tfh cells, such as CXCL13 and CXCR5, may be an 
approach to interrupt T cell support of lymphoma cells. 
Concluding remarks 
The study of mutations arising in B and T cell lymphomas is providing important insights 
about the normal mechanisms acting in GC responses and this work in turn is proving 
informative about the drivers of lymphomagenesis. While the tumor microenvironment is 
unquestionably crucial for lymphomagenesis (Basso and Dalla-Favera, 2015), the potential of a 
supportive T cells to be targeted during lymphomagenesis is only just beginning to be 
appreciated. The evidence discussed in this review suggests that targeting T cell help during GC-
derived lymphomagenesis can provide a complementary approach to B cell targeted therapies for 
treating these lymphomas.  
 
 
 
  
 83 
REFERENCES 
 
Allen, C.D.C., Okada, T., Tang, H.L., and Cyster, J.G. (2007). Imaging of germinal center 
selection events during affinity maturation. Science 315, 528–531. 
Ame-Thomas, P., Le Priol, J., Yssel, H., Caron, G., Pangault, C., Jean, R., Martin, N., Marafioti, 
T., Gaulard, P., Lamy, T., et al. (2012). Characterization of intratumoral follicular helper T cells 
in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26, 1053–1063. 
Auguste, T., Travert, M., Tarte, K., Ame-Thomas, P., Artchounin, C., Martin-Garcia, N., de 
Reynies, A., de Leval, L., Gaulard, P., and Delfau-Larue, M.-H. (2013). ROQUIN/RC3H1 
Alterations Are Not Found in Angioimmunoblastic T-Cell Lymphoma. PLoS ONE 8, e64536–4. 
Álvarez-Prado, Á.F., Pérez-Durán, P., Pérez-García, A., Benguria, A., Torroja, C., de Yébenes, 
V.G., and Ramiro, A.R. (2018). A broad atlas of somatic hypermutation allows prediction of 
activation-induced deaminase targets. Journal of Experimental Medicine 215, 761–771. 
Bannard, O., and Cyster, J.G. (2017). ScienceDirect Germinal centers: programmed for affinity 
maturation and antibody diversification. Current Opinion in Immunology 45, 21–30. 
Bannard, O., McGowan, S.J., Ersching, J., Ishido, S., Victora, G.D., Shin, J.-S., and Cyster, J.G. 
(2016). Ubiquitin-mediated fluctuations in MHC class II facilitate efficient germinal center B 
cell responses. Journal of Experimental Medicine 213, 993–1009. 
Basso, K., and Dalla-Favera, R. (2015). Germinal centres and B cell lymphomagenesis. Nat. 
Rev. Immunol. 15, 172–184. 
 84 
Bende, R.J., Smit, L.A., and van Noesel, C.J.M. (2007). Molecular pathways in follicular 
lymphoma. Leukemia 21, 18–29. 
Berkova, Z., Tao, R.-H., and Samaniego, F. (2009). Milatuzumab – a promising new 
immunotherapeutic agent. Expert Opinion on Investigational Drugs 19, 141–149. 
Béguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K.L., Rosen, M., Shen, H., Yang, 
S.N., Wang, L., Ezponda, T., et al. (2013). EZH2 Is Required for Germinal Center Formation 
and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell 23, 677–692. 
Béguelin, W., Rivas, M.A., Fernández, M.T.C., Teater, M., Purwada, A., Redmond, D., Shen, 
H., Challman, M.F., Elemento, O., Singh, A., et al. (2017). EZH2 enables germinal centre 
formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nat 
Commun 1–16. 
Boice, M., Salloum, D., Mourcin, F., Sanghvi, V., Amin, R., Oricchio, E., Jiang, M., Mottok, A., 
Denis-Lagache, N., Ciriello, G., et al. (2016). Loss of the HVEM Tumor Suppressor in 
Lymphoma and Restoration by Modified CAR-T Cells. Cell 167, 405–418.e413. 
Boisvert, J., Edmondson, S., and Krummel, M.F. (2004). Immunological Synapse Formation 
Licenses CD40-CD40L Accumulations at T-APC Contact Sites. The Journal of Immunology 
173, 3647–3652. 
Bolotin, D.A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I.Z., Putintseva, E.V., and 
Chudakov, D.M. (2015). MiXCR: software for comprehensive adaptive immunity profiling. 
Nature Publishing Group 12, 380–381. 
 85 
Bouska, A., Bi, C., Lone, W., Zhang, W., Kedwaii, A., Heavican, T., Lachel, C.M., Yu, J., Ferro, 
R., Eldorghamy, N., et al. (2017). Adult high-grade B-cell lymphoma with Burkitt lymphoma 
signature: genomic features and potential therapeutic targets. Blood 130, 1819–1831. 
Bride, K., and Teachey, D. (2017). Autoimmune lymphoproliferative syndrome: more than a 
FAScinating disease. F1000Res 6, 1928–16. 
Butt, D., Chan, T.D., Bourne, K., Hermes, J.R., Nguyen, A., Statham, A., O’Reilly, L.A., 
Strasser, A., Price, S., Schofield, P., et al. (2015). FAS Inactivation Releases Unconventional 
Germinal Center B Cells that Escape Antigen Control and Drive IgE and Autoantibody 
Production. Immunity 42, 890–902. 
Calado, D.P., Sasaki, Y., Godinho, S.A., Pellerin, A., Köchert, K., Sleckman, B.P., de Alborán, 
I.M., Janz, M., Rodig, S., and Rajewsky, K. (2012). The cell-cycle regulator c-Myc is essential 
for the formation and maintenance of germinal centers. Nat Immunol 13, 1092–1100. 
Calvo, K.R., Dabir, B., Kovach, A., Devor, C., Bandle, R., Bond, A., Shih, J.H., and Jaffe, E.S. 
(2008). IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood 
112, 3818–3826. 
Cannons, J.L., Qi, H., Lu, K.T., Dutta, M., and Gomez-Rodriguez, J. (2010). Optimal germinal 
center responses require a multistage T cell: B cell adhesion process involving integrins, SLAM-
associated protein, and CD84. Immunity 32, 253–265. 
Carbone, A., Gloghini, A., Gruss, H.J., and Pinto, A. (1995). CD40 ligand is constitutively 
expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of 
follicular lymphomas and Hodgkin's disease. Am. J. Pathol. 147, 912–922. 
 86 
Carreras, J., Lopez-Guillermo, A., Kikuti, Y.Y., Itoh, J., Masashi, M., Ikoma, H., Tomita, S., 
Hiraiwa, S., Hamoudi, R., Rosenwald, A., et al. (2019). High TNFRSF14 and low BTLA are 
associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma 
transformation. Jceh 59, 1–16. 
Casamayor-Palleja, M., Khan, M., and MacLennan, I.C. (1995). A subset of CD4+ memory T 
cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface 
after activation through the T cell receptor complex. Journal of Experimental Medicine 181, 
1293–1301. 
Celis-Gutierrez, J., Blattmann, P., Zhai, Y., Jarmuzynski, N., Ruminski, K., Grégoire, C., 
Ounoughene, Y., Fiore, F., Aebersold, R., Roncagalli, R., et al. (2019). Quantitative 
Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA 
Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep 27, 3315–3330.e3317. 
Challa-Malladi, M., Lieu, Y.K., Califano, O., Holmes, A.B., Bhagat, G., Murty, V.V., 
Dominguez-Sola, D., Pasqualucci, L., and Dalla-Favera, R. (2011). Combined genetic 
inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in 
diffuse large B cell lymphoma. Cancer Cell 20, 728–740. 
Chang, K.-C., Huang, X., Medeiros, L.J., and Jones, D. (2003). Germinal centre-like versus 
undifferentiated stromal immunophenotypes in follicular lymphoma. J. Pathol. 201, 404–412. 
Chao, M.P., Alizadeh, A.A., Tang, C., Myklebust, J.H., Varghese, B., Gill, S., Jan, M., Cha, 
A.C., Chan, C.K., Tan, B.T., et al. (2010). Anti-CD47 antibody synergizes with rituximab to 
promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699–713. 
 87 
Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H., and Riley, J.L. (2004). SHP1 and SHP2 
Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon 
Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The 
Journal of Immunology 173, 945–954. 
Chen, S., Lee, B., Lee, A.Y.-F., Modzelewski, A.J., and He, L. (2016). Highly Efficient Mouse 
Genome Editing by CRISPR Ribonucleoprotein Electroporation of Zygotes. J. Biol. Chem. 291, 
14457–14467. 
Cheung, K.-J.J., Johnson, N.A., Affleck, J.G., Severson, T., Steidl, C., Ben-Neriah, S., Schein, J., 
Morin, R.D., Moore, R., Shah, S.P., et al. (2010). Acquired TNFRSF14 mutations in follicular 
lymphoma are associated with worse prognosis. Cancer Res 70, 9166–9174. 
Cheung, T.C., Oborne, L.M., Steinberg, M.W., Macauley, M.G., Fukuyama, S., Sanjo, H., 
D'Souza, C., Norris, P.S., Pfeffer, K., Murphy, K.M., et al. (2009a). T Cell Intrinsic 
Heterodimeric Complexes between HVEM and BTLA Determine Receptivity to the Surrounding 
Microenvironment. The Journal of Immunology 183, 7286–7296. 
Cheung, T.C., Steinberg, M.W., Oborne, L.M., Macauley, M.G., Fukuyama, S., Sanjo, H., 
D'Souza, C., Norris, P.S., Pfeffer, K., Murphy, K.M., et al. (2009b). Unconventional ligand 
activation of herpesvirus entry mediator signals cell survival. Proc. Natl. Acad. Sci. U.S.a. 106, 
6244–6249. 
Chevrier, S., Kratina, T., Emslie, D., Tarlinton, D.M., and Corcoran, L.M. (2017). IL4 and IL21 
cooperate to induce the high Bcl6 protein level required for germinal center formation. Immunol. 
Cell Biol. 95, 925–932. 
 88 
Choudhuri, K., Llodrá, J., Roth, E.W., Tsai, J., Gordo, S., Wucherpfennig, K.W., Kam, L.C., 
Stokes, D.L., and Dustin, M.L. (2014). Polarized release of T-cell-receptor-enriched 
microvesicles at the immunological synapse. Nature 507, 118–123. 
Chtanova, T., Tangye, S.G., Newton, R., Frank, N., Hodge, M.R., Rolph, M.S., and Mackay, 
C.R. (2004). T Follicular Helper Cells Express a Distinctive Transcriptional Profile, Reflecting 
Their Role as Non-Th1/Th2 Effector Cells That Provide Help for B Cells. The Journal of 
Immunology 173, 68–78. 
Cobaleda, C., Jochum, W., and Busslinger, M. (2007). Conversion of mature B cells into T cells 
by dedifferentiation to uncommitted progenitors. Nature 449, 473–477. 
Cortes, J.R., Ambesi-Impiombato, A., Couronné, L., Quinn, S.A., Kim, C.S., da Silva Almeida, 
A.C., West, Z., Belver, L., Martin, M.S., Scourzic, L., et al. (2018). RHOA G17V Induces T 
Follicular Helper Cell Specification and Promotes Lymphomagenesis. Cancer Cell 33, 259–
273.e7. 
Crotty, S. (2019). T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. 
Immunity 50, 1132–1148. 
de Jong, D., and Fest, T. (2011). The microenvironment in follicular lymphoma. Best Practice & 
Research Clinical Haematology 24, 135–146. 
Dominguez-Sola, D., Victora, G.D., Ying, C.Y., Phan, R.T., Saito, M., Nussenzweig, M.C., and 
Dalla-Favera, R. (2012). The proto-oncogene MYC is required for selection in the germinal 
center and cyclic reentry. Nat Immunol 13, 1083–1091. 
 89 
Duhen, T., Pasero, C., Mallet, F.O., Barbarat, B., Olive, D., and Costello, R.G.T. (2004). LIGHT 
costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T 
cell-dependent B cell terminal differentiation. Eur. J. Immunol. 34, 3534–3541. 
Dustin, M.L., Starr, T., Varma, R., and Thomas, V.K. (2007). Supported Planar Bilayers for 
Study of the Immunological Synapse. Current Protocols in Immunology 76, 18.13.1–18.13.35. 
Egle, A. (2004). VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal 
center hyperplasia. Blood 103, 2276–2283. 
Ellyard, J.I., Chia, T., Rodriguez-Pinilla, S.-M., Martin, J.L., Hu, X., Navarro-Gonzalez, M., 
Garcia, J.F., Delfau-Larue, M.-H., Montes-Moreno, S., Gaulard, P., et al. (2012). Heterozygosity 
for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. Blood 120, 
812–821. 
Engel, P., Eck, M.J., and Terhorst, C. (2003). The SAP and SLAM families in immune responses 
and X-linked lymphoproliferative disease. Nat. Rev. Immunol. 3, 813–821. 
Ersching, J., Efeyan, A., Mesin, L., Jacobsen, J.T., Pasqual, G., Grabiner, B.C., Dominguez-Sola, 
D., Sabatini, D.M., and Victora, G.D. (2017). Germinal Center Selection and Affinity Maturation 
Require Dynamic Regulation of mTORC1 Kinase. Immunity 46, 1045–1058.e1046. 
Fanale, M., Assouline, S., Kuruvilla, J., Solal-Céligny, P., Heo, D.S., Verhoef, G., Corradini, P., 
Abramson, J.S., Offner, F., Engert, A., et al. (2013). Phase IA/II, multicentre, open-label study of 
the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-
Hodgkin or Hodgkin lymphoma. British Journal of Haematology 164, 258–265. 
 90 
Fouquet, G., Marcq, I., Debuysscher, V., Bayry, J., Rabbind Singh, A., Bengrine, A., Nguyen-
Khac, E., Naassila, M., and Bouhlal, H. (2018). Signaling lymphocytic activation molecules 
Slam and cancers: friends or foes? Oncotarget 9, 16248–16262. 
Gardell, J.L., and Parker, D.C. (2016). CD40L is transferred to antigen-presenting B cells during 
delivery of T-cell help. Eur. J. Immunol. 47, 41–50. 
Gavrieli, M., and Murphy, K.M. (2006). Association of Grb-2 and PI3K p85 with 
phosphotyrosile peptides derived from BTLA. Biochem. Biophys. Res. Commun. 345, 1440–
1445. 
Gavrieli, M., Watanabe, N., Loftin, S.K., Murphy, T.L., and Murphy, K.M. (2003). 
Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T 
lymphocyte attenuator required for association with protein tyrosine phosphatases SHP1 and 
SHP2. Biochem. Biophys. Res. Commun. 312, 1236–1243. 
Ghia, P., Boussiotis, V.A., Schultze, J.L., Cardoso, A.A., Dorfman, D.M., Gribben, J.G., 
Freedman, A.S., and Nadler, L.M. (1998). Unbalanced expression of bcl-2 family proteins in 
follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 91, 244–251. 
Gitlin, A.D., Shulman, Z., and Nussenzweig, M.C. (2014). Clonal selection in the germinal 
centre by regulated proliferation and hypermutation. Nature 509, 637–640. 
Godfrey, J., Tumuluru, S., Bao, R., Leukam, M., Venkataraman, G., Phillip, J., Fitzpatrick, C., 
McElherne, J., MacNabb, B.W., Orlowski, R., et al. (2019). PD-L1 gene alterations identify a 
subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype. Blood 133, 
2279–2290. 
 91 
Gonzalez, D.G., Cote, C.M., Patel, J.R., Smith, C.B., Zhang, Y., Nickerson, K.M., Zhang, T., 
Kerfoot, S.M., and Haberman, A.M. (2018). Nonredundant Roles of IL-21 and IL-4 in the 
Phased Initiation of Germinal Center B Cells and Subsequent Self-Renewal Transitions. J. 
Immunol. 201, 3569–3579. 
Good-Jacobson, K.L., Szumilas, C.G., Chen, L., Sharpe, A.H., Tomayko, M.M., and Shlomchik, 
M.J. (2010). PD-1 regulates germinal center B cell survival and the formation and affinity of 
long-lived plasma cells. Nat Immunol 11, 535–542. 
Green, J.A., Suzuki, K., Cho, B., Willison, L.D., Palmer, D., Allen, C.D.C., Schmidt, T.H., Xu, 
Y., Proia, R.L., Coughlin, S.R., et al. (2011). The sphingosine 1-phosphate receptor S1P2 
maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat 
Immunol 12, 672–680. 
Hams, E., McCarron, M.J., Amu, S., Yagita, H., Azuma, M., Chen, L., and Fallon, P.G. (2011). 
Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively 
regulating the generation of T follicular helper cells. J. Immunol. 186, 5648–5655. 
Hao, Z., Duncan, G.S., Seagal, J., Su, Y.-W., Hong, C., Haight, J., Chen, N.-J., Elia, A., 
Wakeham, A., Li, W.Y., et al. (2008). Fas Receptor Expression in Germinal-Center B Cells Is 
Essential for T and B Lymphocyte Homeostasis. Immunity 29, 615–627. 
Hashwah, H., Schmid, C.A., Kasser, S., Bertram, K., Stelling, A., Manz, M.G., and Müller, A. 
(2017). Inactivation of CREBBP expands the germinal center B cell compartment, down-
regulates MHCII expression and promotes DLBCL growth. Proc. Natl. Acad. Sci. U.S.a. 114, 
9701–9706. 
 92 
Hömig-Hölzel, C., Hojer, C., Rastelli, J., Casola, S., Strobl, L.J., Müller, W., Quintanilla-
Martinez, L., Gewies, A., Ruland, J., Rajewsky, K., et al. (2008). Constitutive CD40 signaling in 
B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis. 
Journal of Experimental Medicine 205, 1317–1329. 
Hsu, H., Solovyev, I., Colombero, A., Elliott, R., Kelley, M., and Boyle, W.J. (1997). ATAR, a 
novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5. J. 
Biol. Chem. 272, 13471–13474. 
Huang, B., Gomez-Rodriguez, J., Preite, S., Garrett, L.J., Harper, U.L., and Schwartzberg, P.L. 
(2016). CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports 
Positive Signaling Roles in NKT Cell Development. PLoS ONE 11, e0156072–19. 
Huet, S., Sujobert, P., and Salles, G. (2018). From genetics to the clinic: a translational 
perspective on follicular lymphoma. Nature Publishing Group 18, 224–239. 
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M.J., Wallweber, H.A., Sasmal, D.K., Huang, J., 
Kim, J.M., Mellman, I., et al. (2017). T cell costimulatory receptor CD28 is a primary target for 
PD-1–mediated inhibition. Science 355, 1428–1433. 
Iezzi, G., Sonderegger, I., Ampenberger, F., Schmitz, N., Marsland, B.J., and Kopf, M. (2009). 
CD40–CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce 
development of IL-17-producing CD4+ T cells. Proceedings of the National Academy of 
Sciences 106, 876–881. 
Iqbal, J., Meyer, P.N., Smith, L.M., Johnson, N.A., Vose, J.M., Greiner, T.C., Connors, J.M., 
Staudt, L.M., Rimsza, L., Jaffe, E., et al. (2011). BCL2 Predicts Survival in Germinal Center B-
 93 
cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. 
Clinical Cancer Research 17, 7785–7795. 
Iqbal, J., Weisenburger, D.D., Greiner, T.C., Vose, J.M., McKeithan, T., Kucuk, C., Geng, H., 
Deffenbacher, K., Smith, L., Dybkær, K., et al. (2010). Molecular signatures to improve 
diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell 
lymphoma. Blood 115, 1026–1036. 
Kasahara, H., Kakimoto, T., Saito, H., Akuta, K., Yamamoto, K., Ujiie, H., Sugahara, H., 
Hoshida, Y., and Sakoda, H. (2013). Successful treatment with rituximab for 
angioimmunoblastic T-cell lymphoma. Leukemia Research Reports 2, 36–38. 
Kashiwakuma, D., Suto, A., Hiramatsu, Y., Ikeda, K., Takatori, H., Suzuki, K., Kagami, S.-I., 
Hirose, K., Watanabe, N., Iwamoto, I., et al. (2010). B and T lymphocyte attenuator suppresses 
IL-21 production from follicular Th cells and subsequent humoral immune responses. J. 
Immunol. 185, 2730–2736. 
Kishi, Y., Aiba, Y., Higuchi, T., Furukawa, K., Tokuhisa, T., Takemori, T., and Tsubata, T. 
(2010). Augmented Antibody Response with Premature Germinal Center Regression in CD40L 
Transgenic Mice. The Journal of Immunology 185, 211–219. 
Koguchi, Y., Thauland, T.J., Slifka, M.K., and Parker, D.C. (2007). Preformed CD40 ligand 
exists in secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on 
the cell surface in an antigen-specific manner. Blood 110, 2520–2527. 
Koguchi, Y., Buenafe, A.C., Thauland, T.J., Gardell, J.L., Bivins-Smith, E.R., Jacoby, D.B., 
Slifka, M.K., and Parker, D.C. (2012). Preformed CD40L Is Stored in Th1, Th2, Th17, and T 
 94 
Follicular Helper Cells as Well as CD4+8− Thymocytes and Invariant NKT Cells but Not in 
Treg Cells. PLoS ONE 7, e31296–14. 
Koncz, G., and Hueber, A.-O. (2012). The Fas/CD95 Receptor Regulates the Death of 
Autoreactive B Cells and the Selection of Antigen-Specific B Cells. Front Immunol 3, 207. 
Kondo, E., Yoshino, T., Nishiuchi, R., Sakuma, I., Nishizaki, K., Kayagaki, N., Yagita, H., and 
Akagi, T. (1997). Expression of Fas ligand mRNA in germinal centres of the human tonsil. J. 
Pathol. 183, 75–79. 
Kopf, M., Le Gros, G., Coyle, A.J., Kosco-Vilbois, M., and Brombacher, F. (1995). Immune 
responses of IL-4, IL-5, IL-6 deficient mice. Immunological Reviews 148, 45–69. 
Kotsiou, E., Okosun, J., Besley, C., Iqbal, S., Matthews, J., Fitzgibbon, J., Gribben, J.G., and 
Davies, J.K. (2016). TNFRSF14 aberrations in follicular lymphoma increase clinically 
significant allogeneic T-cell responses. Blood 1–40. 
Kuleshov, M.V., Jones, M.R., Rouillard, A.D., Fernandez, N.F., Duan, Q., Wang, Z., Koplev, S., 
Jenkins, S.L., Jagodnik, K.M., Lachmann, A., et al. (2016). Enrichr: a comprehensive gene set 
enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97. 
Lackraj, T., Goswami, R., and Kridel, R. (2018). Pathogenesis of follicular lymphoma. Best 
Practice & Research Clinical Haematology 31, 2–14. 
Launay, E., Pangault, C., Bertrand, P., Jardin, F., Lamy, T., Tilly, H., Tarte, K., Bastard, C., and 
Fest, T. (2012). High rate of TNFRSF14 gene alterations related to 1p36 region in de novo 
follicular lymphoma and impact on prognosis. Leukemia 26, 559–562. 
 95 
Lavoie, T.B., Drohan, W.N., and Smith-Gill, S.J. (1992). Experimental analysis by site-directed 
mutagenesis of somatic mutation effects on affinity and fine specificity in antibodies specific for 
lysozyme. The Journal of Immunology 148, 503–513. 
Le, K.S., Thibult, M.L., Just-Landi, S., Pastor, S., Gondois-Rey, F., Granjeaud, S., Broussais, F., 
Bouabdallah, R., Colisson, R., Caux, C., et al. (2016). Follicular B Lymphomas Generate 
Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-
ICOS/ICOSL Therapy. Cancer Res 76, 4648–4660. 
Lesley, R., Kelly, L.M., Xu, Y., and Cyster, J.G. (2006). Naive CD4 T cells constitutively 
express CD40L and augment autoreactive B cell survival. Proceedings of the National Academy 
of Sciences 103, 10717–10722. 
Liu, D., Xu, H., Shih, C., Wan, Z., Ma, X., Ma, W., Luo, D., and Qi, H. (2014). T-B-cell 
entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction. Nature. 
Liu, Y., Hernandez, A.M., Shibata, D., and Cortopassi, G.A. (1994). BCL2 translocation 
frequency rises with age in humans. Proceedings of the National Academy of Sciences 91, 8910–
8914. 
Losman, J.A., Chen, X.P., Hilton, D., and Rothman, P. (1999). Cutting edge: SOCS-1 is a potent 
inhibitor of IL-4 signal transduction. The Journal of Immunology 162, 3770–3774. 
Lossos, I.S., and Gascoyne, R.D. (2011). Transformation of follicular lymphoma. Best Practice 
& Research Clinical Haematology 24, 147–163. 
 96 
Lu, E., Wolfreys, F.D., Muppidi, J.R., Xu, Y., and Cyster, J.G. (2019). S-Geranylgeranyl-L-
glutathione is a ligand for human B cell-confinement receptor P2RY8. Nature 567, 244–248. 
Luo, W., Weisel, F., and Shlomchik, M.J. (2018). B Cell Receptor and CD40 Signaling Are 
Rewired for Synergistic Induction of the c-Myc Transcription Factor in Germinal Center B Cells. 
Immunity 48, 313–326.e315. 
MacLennan, I.C. (1994). Germinal centers. Annu. Rev. Immunol. 12, 117–139. 
Manso, B.A., Wenzl, K., Asmann, Y.W., Maurer, M.J., Manske, M., Yang, Z.-Z., Slager, S.L., 
Nowakowski, G.S., Ansell, S.M., Witzig, T.E., et al. (2017). Whole-exome analysis reveals 
novel somatic genomic alterations associated with cell of origin in diffuse large B-cell 
lymphoma. Blood Cancer J 7, e553–e553. 
Martinov, T., Swanson, L.A., Breed, E.R., Tucker, C.G., Dwyer, A.J., Johnson, J.K., Mitchell, 
J.S., Sahli, N.L., Wilson, J.C., Singh, L.M., et al. (2019). Programmed Death-1 Restrains the 
Germinal Center in Type 1 Diabetes. J. Immunol. 203, 844–852. 
Mayer, C.T., Gazumyan, A., Kara, E.E., Gitlin, A.D., Golijanin, J., Viant, C., Pai, J., Oliveira, 
T.Y., Wang, Q., Escolano, A., et al. (2017). The microanatomic segregation of selection by 
apoptosis in the germinal center. Science 358. 
Mayya, V., Judokusumo, E., Shah, E.A., Peel, C.G., Neiswanger, W., Depoil, D., Blair, D.A., 
Wiggins, C.H., Kam, L.C., and Dustin, M.L. (2018). Durable Interactions of T Cells with T Cell 
Receptor Stimuli in the Absence of a Stable Immunological Synapse. Cell Rep 22, 340–349. 
 97 
Mesin, L., Ersching, J., and Victora, G.D. (2016). Germinal Center B Cell Dynamics. Immunity 
45, 471–482. 
Milpied, P., Cervera-Marzal, I., Mollichella, M.-L., Tesson, B., Brisou, G., Traverse-Glehen, A., 
Salles, G., Spinelli, L., and Nadel, B. (2018). Human germinal center transcriptional programs 
are de-synchronized in B cell lymphoma. Nat Immunol 1–19. 
Mintz, M.A., Felce, J.H., Chou, M.Y., Mayya, V., Xu, Y., Shui, J.-W., An, J., Li, Z., Marson, A., 
Okada, T., et al. (2019). The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B 
Cells and Functions as a Cell- Extrinsic Suppressor in Lymphomagenesis. Immunity 51, 310–
323.e317. 
Mlynarczyk, C., Fontán, L., and Melnick, A. (2019). Germinal center-derived lymphomas: The 
darkest side of humoral immunity. Immunological Reviews 288, 214–239. 
Mulder, T.A., Wahlin, B.E., Österborg, A., and Palma, M. (2019). Targeting the Immune 
Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application. 
Cancers (Basel) 11. 
Muppidi, J.R., Schmitz, R., Green, J.A., Xiao, W., Larsen, A.B., Braun, S.E., An, J., Xu, Y., 
Rosenwald, A., Ott, G., et al. (2014). Loss of signalling via Gα13 in germinal centre B-cell-
derived lymphoma. Nature 516, 254–258. 
Murphy, K.M., Nelson, C.A., and Sedy, J.R. (2006). Balancing co-stimulation and inhibition 
with BTLA and HVEM. Nat. Rev. Immunol. 6, 671–681. 
 98 
Müschen, M., Rajewsky, K., Krönke, M., and Küppers, R. (2002). The origin of CD95-gene 
mutations in B-cell lymphoma. Trends Immunol. 23, 75–80. 
Myklebust, J.H., Irish, J.M., Brody, J., Czerwinski, D.K., Houot, R., Kohrt, H.E., Timmerman, 
J., Said, J., Green, M.R., Delabie, J., et al. (2013). High PD-1 expression and suppressed 
cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T 
cells. Blood 121, 1367–1376. 
Nurieva, R.I., Chung, Y., Martinez, G.J., Yang, X.O., Tanaka, S., Matskevitch, T.D., Wang, Y.-
H., and Dong, C. (2009). Bcl6 mediates the development of T follicular helper cells. Science 
325, 1001–1005. 
Ochando, J., and Braza, M.S. (2017). T follicular helper cells: a potential therapeutic target in 
follicular lymphoma. Oncotarget 8, 112116–112131. 
Odejide, O., Weigert, O., Lane, A.A., Toscano, D., Lunning, M.A., Kopp, N., Kim, S., van 
Bodegom, D., Bolla, S., Schatz, J.H., et al. (2014). A targeted mutational landscape of 
angioimmunoblastic T-cell lymphoma. Blood 123, 1293–1296. 
Ogilvy, S., Metcalf, D., Print, C.G., Bath, M.L., Harris, A.W., and Adams, J.M. (1999). 
Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple 
lineages and enhances progenitor cell survival. Proceedings of the National Academy of 
Sciences 96, 14943–14948. 
Owada, T., Watanabe, N., Oki, M., Oya, Y., Saito, Y., Saito, T., Iwamoto, I., Murphy, T.L., 
Murphy, K.M., and Nakajima, H. (2010). Activation-induced accumulation of B and T 
 99 
lymphocyte attenuator at the immunological synapse in CD4+ T cells. Journal of Leukocyte 
Biology 87, 425–432. 
Oya, Y., Watanabe, N., Owada, T., Oki, M., Hirose, K., Suto, A., Kagami, S.-I., Nakajima, H., 
Kishimoto, T., Iwamoto, I., et al. (2008). Development of autoimmune hepatitis-like disease and 
production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. 
Arthritis & Rheumatism 58, 2498–2510. 
Paiva, C., Godbersen, J.C., Rowland, T., Danilova, O.V., Danes, C., Berger, A., and Danilov, 
A.V. (2017). Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to 
death receptor-mediated apoptosis. Oncotarget 8, 21128–21139. 
Pangault, C., Ame-Thomas, P., Ruminy, P., Rossille, D., Caron, G., Baia, M., De Vos, J., 
Roussel, M., Monvoisin, C., Lamy, T., et al. (2010). Follicular lymphoma cell niche: 
identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 24, 2080–2089. 
Papa, I., Saliba, D., Ponzoni, M., Bustamante, S., Canete, P.F., Gonzalez-Figueroa, P., 
McNamara, H.A., Valvo, S., Grimbaldeston, M., Sweet, R.A., et al. (2017). TFH-derived 
dopamine accelerates productive synapses in germinal centres. Nature 547, 318–323. 
Paul, W.E. (2015). History of interleukin-4. Cytokine 75, 3–7. 
Paus, D., Phan, T.G., Chan, T.D., Gardam, S., Basten, A., and Brink, R. (2006). Antigen 
recognition strength regulates the choice between extrafollicular plasma cell and germinal center 
B cell differentiation. Journal of Experimental Medicine 203, 1081–1091. 
 100 
Qi, H., Cannons, J.L., Klauschen, F., Schwartzberg, P.L., and Germain, R.N. (2008). SAP-
controlled T–B cell interactions underlie germinal centre formation. Nature 455, 764–769. 
Rabkin, C.S., Hirt, C., Janz, S., and Dolken, G. (2008). t(14;18) Translocations and Risk of 
Follicular Lymphoma. JNCI Monographs 2008, 48–51. 
Rawal, S., Chu, F., Zhang, M., Park, H.J., Nattamai, D., Kannan, S., Sharma, R., Delgado, D., 
Chou, T., Lin, H.Y., et al. (2013). Cross Talk between Follicular Th Cells and Tumor Cells in 
Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. The 
Journal of Immunology 190, 6681–6693. 
Reinhardt, R.L., Liang, H.-E., and Locksley, R.M. (2009). Cytokine-secreting follicular T cells 
shape the antibody repertoire. Nat Immunol 10, 385–393. 
Ritthipichai, K., Haymaker, C.L., Martinez, M., Aschenbrenner, A., Yi, X., Zhang, M., Kale, C., 
Vence, L.M., Roszik, J., Hailemichael, Y., et al. (2017). Multifaceted Role of BTLA in the 
Control of CD8+ T-cell Fate after Antigen Encounter. Clinical Cancer Research 23, 6151–6164. 
Rota, G., Niogret, C., Dang, A.T., Barros, C.R., Fonta, N.P., Alfei, F., Morgado, L., Zehn, D., 
Birchmeier, W., Vivier, E., et al. (2018). Shp2 Is Dispensable for Establishing T Cell Exhaustion 
and for PD-1 Signaling In Vivo. Cell Rep 23, 39–49. 
Ruedl, C., Bachmann, M.F., and Kopf, M. (2000). The antigen dose determines T helper subset 
development by regulation of CD40 ligand. Eur. J. Immunol. 30, 2056–2064. 
Sacco, M.G., Ungari, M., Catò, E.M., Villa, A., Strina, D., Notarangelo, L.D., Jonkers, J., Zecca, 
L., Facchetti, F., and Vezzoni, P. (2000). Lymphoid abnormalities in CD40 ligand transgenic 
 101 
mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin 
M (IgM) syndrome. Cancer Gene Ther. 7, 1299–1306. 
Sage, P.T., Francisco, L.M., Carman, C.V., and Sharpe, A.H. (2012). The receptor PD-1 controls 
follicular regulatory T cells in the lymph nodes and blood. Nat Immunol 14, 152–161. 
Schmitz, N., and de Leval, L. (2016). How I manage peripheral T-cell lymphoma, not otherwise 
specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the 
future. British Journal of Haematology 176, 851–866. 
Schmitz, R., Wright, G.W., Huang, D.W., Johnson, C.A., Phelan, J.D., Wang, J.Q., Roulland, S., 
Kasbekar, M., Young, R.M., Shaffer, A.L., et al. (2018). Genetics and Pathogenesis of Diffuse 
Large B-Cell Lymphoma. N. Engl. J. Med. 378, 1396–1407. 
Schmitz, R., Young, R.M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M., Wright, G., Shaffer, 
A.L., Hodson, D.J., Buras, E., et al. (2012). Burkitt lymphoma pathogenesis and therapeutic 
targets from structural and functional genomics. Nature 490, 116–120. 
Sedy, J.R., Gavrieli, M., Potter, K.G., Hurchla, M.A., Lindsley, R.C., Hildner, K., Scheu, S., 
Pfeffer, K., Ware, C.F., Murphy, T.L., et al. (2004). B and T lymphocyte attenuator regulates T 
cell activation through interaction with herpesvirus entry mediator. Nat Immunol 6, 90–98. 
Seo, G.-Y., Shui, J.-W., Takahashi, D., Song, C., Wang, Q., Kim, K., Mikulski, Z., Chandra, S., 
Giles, D.A., Zahner, S., et al. (2018). LIGHT-HVEM Signaling in Innate Lymphoid Cell Subsets 
Protects Against Enteric Bacterial Infection. Cell Host and Microbe 24, 249–260.e4. 
 102 
Shi, J., Hou, S., Fang, Q., Liu, X., Liu, X., and Qi, H. (2018). PD-1 Controls Follicular T Helper 
Cell Positioning and Function. Immunity 49, 264–274.e264. 
Shinnakasu, R., Inoue, T., Kometani, K., Moriyama, S., Adachi, Y., Nakayama, M., Takahashi, 
Y., Fukuyama, H., Okada, T., and Kurosaki, T. (2016). Regulated selection of germinal-center 
cells into the memory B cell compartment. Nat Immunol 17, 1–11. 
Shui, J.-W., Larange, A., Kim, G., Vela, J.L., Zahner, S., Cheroutre, H., and Kronenberg, M. 
(2012). HVEM signalling at mucosal barriers provides host defence against pathogenic bacteria. 
Nature 488, 222–225. 
Shulman, Z., Gitlin, A.D., Weinstein, J.S., Lainez, B., Esplugues, E., Flavell, R.A., Craft, J.E., 
and Nussenzweig, M.C. (2014). Dynamic signaling by T follicular helper cells during germinal 
center B cell selection. Science 345, 1058–1062. 
Smeltzer, J.P., Jones, J.M., Ziesmer, S.C., Grote, D.M., Xiu, B., Ristow, K.M., Yang, Z.Z., 
Nowakowski, G.S., Feldman, A.L., Cerhan, J.R., et al. (2014). Pattern of CD14+ follicular 
dendritic cells and PD1+ T cells independently predicts time to transformation in follicular 
lymphoma. Clinical Cancer Research 20, 2862–2872. 
Steinberg, M.W., Cheung, T.C., and Ware, C.F. (2011). The signaling networks of the 
herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunological Reviews 244, 
169–187. 
Straus, S.E., Jaffe, E.S., Puck, J.M., Dale, J.K., Elkon, K.B., Rösen-Wolff, A., Peters, A.M., 
Sneller, M.C., Hallahan, C.W., Wang, J., et al. (2001). The development of lymphomas in 
 103 
families with autoimmune lymphoproliferative syndrome with germline Fas mutations and 
defective lymphocyte apoptosis. Blood 98, 194–200. 
Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T.K., Takemoto, T., and 
Okazaki, T. (2019). Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for 
optimal T cell responses. Science 364, 558–566. 
Sungalee, S., Mamessier, E., Morgado, E., Grégoire, E., Brohawn, P.Z., Morehouse, C.A., Jouve, 
N., Monvoisin, C., Menard, C., Debroas, G., et al. (2014). Germinal center reentries of BCL2-
overexpressing B cells drive follicular lymphoma progression. J. Clin. Invest. 124, 5337–5351. 
Takahashi, Y., Ohta, H., and Takemori, T. (2001). Fas is required for clonal selection in germinal 
centers and the subsequent establishment of the memory B cell repertoire. Immunity 14, 181–
192. 
Tang, J., Zha, J., Guo, X., Shi, P., and Xu, B. (2017). CXCR5+CD8+ T cells present elevated 
capacity in mediating cytotoxicity toward autologous tumor cells through interleukin 10 in 
diffuse large B-cell lymphoma. International Immunopharmacology 50, 146–151. 
Totten, S., Gaucher, D., Morin, R.D., Assouline, S., Connors, J.M., Marra, M.A., Scott, D.W., 
Gascoyne, R.D., Pelletier, J., Mann, K.K., et al. (2014). FAS Mutations Accelerate Lymphoma 
Growth and Induce Therapeutic Resistance. Blood 124, 3018. 
Travert, M., Ame-Thomas, P., Pangault, C., Morizot, A., Micheau, O., Semana, G., Lamy, T., 
Fest, T., Tarte, K., and Guillaudeux, T. (2008). CD40 ligand protects from TRAIL-induced 
apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP 
and Bcl-xL. J. Immunol. 181, 1001–1011. 
 104 
Tsukamoto, T., Nakano, M., Sato, R., Adachi, H., Kiyota, M., Kawata, E., Uoshima, N., 
Yasukawa, S., Chinen, Y., Mizutani, S., et al. (2017). High-risk follicular lymphomas harbour 
more somatic mutations including those in the AID-motif. Scientific Reports 1–10. 
Turqueti-Neves, A., Otte, M., da Costa, O.P., Höpken, U.E., Lipp, M., Buch, T., and Voehringer, 
D. (2014). B-cell-intrinsic STAT6 signaling controls germinal center formation. Eur. J. 
Immunol. 44, 2130–2138. 
Vendel, A.C., Calemine-Fenaux, J., Izrael-Tomasevic, A., Chauhan, V., Arnott, D., and Eaton, 
D.L. (2009). B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk 
and BLNK. J. Immunol. 182, 1509–1517. 
Verdière, L., Mourcin, F., and Tarte, K. (2018). Microenvironment signaling driving 
lymphomagenesis. Current Opinion in Hematology 25, 335–345. 
Vijayanand, P., Seumois, G., Simpson, L.J., Abdul-Wajid, S., Baumjohann, D., Panduro, M., 
Huang, X., Interlandi, J., Djuretic, I.M., Brown, D.R., et al. (2012). Interleukin-4 Production by 
Follicular Helper T Cells Requires the Conserved Il4 Enhancer Hypersensitivity Site V. 
Immunity 36, 175–187. 
Wakamatsu, E., Mathis, D., and Benoist, C. (2013). Convergent and divergent effects of 
costimulatory molecules in conventional and regulatory CD4+ T cells. Proceedings of the 
National Academy of Sciences 110, 1023–1028. 
Wan, Z., Lin, Y., Zhao, Y., and Qi, H. (2019). TFH cells in bystander and cognate interactions 
with B cells. Immunological Reviews 288, 28–36. 
 105 
Wang, Y., Subudhi, S.K., Anders, R.A., Lo, J., Sun, Y., Blink, S., Wang, Y., Wang, J., Liu, X., 
Mink, K., et al. (2005). The role of herpesvirus entry mediator as a negative regulator of T cell-
mediated responses. J. Clin. Invest. 115, 711–717. 
Ward-Kavanagh, L.K., Lin, W.W., Sedy, J.R., and Ware, C.F. (2016). The TNF Receptor 
Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity 44, 1005–1019. 
Watanabe, N., Gavrieli, M., Sedy, J.R., Yang, J., Fallarino, F., Loftin, S.K., Hurchla, M.A., 
Zimmerman, N., Sim, J., Zang, X., et al. (2003). BTLA is a lymphocyte inhibitory receptor with 
similarities to CTLA-4 and PD-1. Nat Immunol 4, 670–679. 
Weber, J.P., Fuhrmann, F., Feist, R.K., Lahmann, A., Baz, Al, M.S., Gentz, L.-J., Vu Van, D., 
Mages, H.W., Haftmann, C., Riedel, R., et al. (2015). ICOS maintains the T follicular helper cell 
phenotype by down-regulating Krüppel-like factor 2. Journal of Experimental Medicine 212, 
217–233. 
Weinstein, J.S., Herman, E.I., Lainez, B., Licona-Limón, P., Esplugues, E., Flavell, R., and 
Craft, J. (2016). TFH cells progressively differentiate to regulate the germinal center response. 
Nat Immunol 17, 1197–1205. 
Wu, T.-H., Zhen, Y., Zeng, C., Yi, H.-F., and Zhao, Y. (2007). B and T lymphocyte attenuator 
interacts with CD3ζ and inhibits tyrosine phosphorylation of TCRζ complex during T-cell 
activation. Immunol. Cell Biol. 85, 590–595. 
Xu, H., Li, X., Liu, D., Li, J., Zhang, X., Chen, X., Hou, S., Peng, L., Xu, C., Liu, W., et al. 
(2013). Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven 
motility. Nature 496, 523–527. 
 106 
Xu-Monette, Z.Y., Xiao, M., Au, Q., Padmanabhan, R., Xu, B., Hoe, N., Rodríguez-Perales, S., 
Torres-Ruiz, R., Manyam, G.C., Visco, C., et al. (2019). Immune Profiling and Quantitative 
Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune 
Microenvironment of DLBCL. Cancer Immunology Research 7, 644–657. 
Xu-Monette, Z.Y., Li, L., Byrd, J.C., Jabbar, K.J., Manyam, G.C., Maria de Winde, C., van den 
Brand, M., Tzankov, A., Visco, C., Wang, J., et al. (2016). Assessment of CD37 B-cell antigen 
and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood 
128, 3083–3100. 
Yang, Z.Z., Kim, H.J., Villasboas, J.C., Price-Troska, T., Jalali, S., Wu, H., Luchtel, R.A., 
Polley, M.-Y.C., Novak, A.J., and Ansell, S.M. (2019). Mass Cytometry Analysis Reveals that 
Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular 
Lymphoma. Cell Rep 26, 2178–2193.e3. 
Yang, Z., Sullivan, B.M., and Allen, C.D.C. (2012). Fluorescent In Vivo Detection Reveals that 
IgE+ B Cells Are Restrained by an Intrinsic Cell Fate Predisposition. Immunity 36, 857–872. 
Yeh, C.-H., Nojima, T., Kuraoka, M., and Kelsoe, G. (2018). Germinal center entry not selection 
of B cells is controlled by peptide-MHCII complex density. Nat Commun 9, 928. 
Yi, T., and Cyster, J.G. (2013). EBI2-mediated bridging channel positioning supports splenic 
dendritic cell homeostasis and particulate antigen capture. eLife 2, 309–319. 
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., and 
Saito, T. (2012). Programmed cell death 1 forms negative costimulatory microclusters that 
 107 
directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. Journal of 
Experimental Medicine 209, 1201–1217. 
Yu, D., Cozma, D., Park, A., and Thomas-Tikhonenko, A. (2005). Functional validation of genes 
implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. 
Ann. N. Y. Acad. Sci. 1059, 145–159. 
Yusuf, I., Kageyama, R., Monticelli, L., Johnston, R.J., DiToro, D., Hansen, K., Barnett, B., and 
Crotty, S. (2010). Germinal Center T Follicular Helper Cell IL-4 Production Is Dependent on 
Signaling Lymphocytic Activation Molecule Receptor (CD150). The Journal of Immunology 
185, 190–202. 
Zhao, Y., Zheng, Z., Cohen, C.J., Gattinoni, L., Palmer, D.C., Restifo, N.P., Rosenberg, S.A., 
and Morgan, R.A. (2005). High-Efficiency Transfection of Primary Human and Mouse T 
Lymphocytes Using RNA Electroporation. Molecular Therapy 13, 151–159. 
Zhu, Y., Yao, S., Augustine, M.M., Xu, H., Wang, J., Sun, J., Broadwater, M., Ruff, W., Luo, L., 
Zhu, G., et al. (2016). Neuron-specific SALM5 limits inflammation in the CNS via its interaction 
with HVEM. Science Advances 2, e1500637–e1500637. 
Zotos, D., Coquet, J.M., Zhang, Y., Light, A., D'Costa, K., Kallies, A., Corcoran, L.M., Godfrey, 
D.I., Toellner, K.-M., Smyth, M.J., et al. (2010). IL-21 regulates germinal center B cell 
differentiation and proliferation through a B cell-intrinsic mechanism. J. Exp. Med. 207, 365–
378. 
 
Publishing Agreement  
It is the policy of the University to encourage the distribution of all theses, 
dissertations, and manuscripts. Copies of all UCSF theses, dissertations, and 
manuscripts will be routed to the library via the Graduate Division. The library will 
make all theses, dissertations, and manuscripts accessible to the public and will 
preserve these to the best of their abilities, in perpetuity.    
Please sign the following statement:   
I hereby grant permission to the Graduate Division of the University of California, San 
Francisco to release copies of my thesis, dissertation, or manuscript to the Campus 
Library to provide access and preservation, in whole or in part, in perpetuity.  
_____________________________________                                                               
                                      Author Signature 
________________
  Date 

